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Abstract 
 
 
Lysophosphatidic acid (LPA) is a naturally occurring bioactive phospholipid. It has a 
wide array of biological effects like cell proliferation, survival, migration, apoptosis 
invasion, wound healing and angiogenesis. Autotaxin (ATX) was identified as an 
autocrine tumor cell motility factor from A2058 melanoma conditioned medium. ATX 
has lysophospholipase D enzyme activity and is responsible for the cleavage of 
lysophophatidylcholine (LPC) leading to the generation of LPA. Antagonists of 
Autotaxin would have a potential therapeutic application in cancer research. Chapter 1 is 
an introduction of LPA and autotaxin. It provides the background and significance of the 
research. Chapter 2 explores the synthesis of the stereoisomers of 3-CCPA and the 
pharmacological activites of these isomers. Chapter 3 discusses the design and synthesis 
of benzyl and naphthalene-methyl phosphonic acid inhibitors of autotaxin with 
anti-invasive and anti-metastatic actions. Chapter 4 elaborates on the search for new 
non-lipid, drug like LPA analogs. Chapter 5 provides an overview of the work detailed in 
the dissertation; as well as future directions that will help further the scope of these 
projects.  
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Lysophosphatidic acid(LPA) is a naturally occurring bioactive phospholipid. It has a 
wide array of biological effects like cell proliferation, survival, migration, apoptosis 
invasion, wound healing and angiogenesis.1 Lysphosphatidic acid (LPA, Figure 1.1) is a 
simple phospholipid and consists of a glycerol backbone with a hydroxyl group at the 
sn-2 (or sn-1) position, a phosphate group at the sn-3 position, and a fatty acid chain at 
the sn-1 (or sn-2) position. Most of the LPA fatty acids are long chain saturated (16:0, 
18:0) or unsaturated (18:1, 18:2, 20:4) fatty acids linked to the glycerol backbone by acyl 
or alkyl linkage. Significant levels of LPA have been detected extracelluarly in biological 
fluids such as serum,2,3 sputum,4 seminal fluid,5 and bronchoalveolar lavage fluid.4 In 
addition, platelets, cancer cells and adipocytes, also generate extracellular LPA.6 
 
 
Biosynthesis and Catabolism of LPA  
 
LPA can be generated by several different mechanisms. Extracellular LPA is formed 
catalytically by cleavage of lysophospholipids by lysophospholipase D (lyso-PLD). 
Extracelular LPA is also generated via secreted PLA enzymes, phosphatidyl serine 
specific PLA1 and secretory PLA2. Secretory type-II PLA2 and phosphatidic acid 
selective PLA1, cleave surface exposed phosphatidic acid. LPA is also generated 
extracellularly by mild oxidation of low density lipoproteins.  
 
The LysoPLD that generates LPA has recently been found to be identical to the cell 
motility stimulating factor, autotaxin (ATX). ATX also produces cyclic phosphatidic acid 
(CPA) which is a naturally occuring analog of LPA in which the sn-2 hydroxy group 
forms a 5-membered ring with the sn-3 phosphate.7 In mammalian cells, CPA is 
generated intracellularly by PLD2 and acts as an inhibitor of PPARγ.8 3-carba analogue 
(3CCPA 18:1) is a selective weak agonist of LPA5/GPR92 that fails to activate LPA1/2/3/4 
and also inhibits ATX.9,10  
 
It is produced intracelluarly by the enzymes glycerophosphate acyltransferase (GPAT),11 
acylglycerol kinase (AGK)12 and by the reduction of acyl dihydroxy acetone phosphate 
(acyl DHAP)13 with the help of a reductase. Major pathway for the intracellular 
production of LPA was proven to be via Ca2 + independent Phospholipase A2.14 
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Figure 1.1. LPA. 
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Extracellular Generation of LPA 
 
 
The Lyso-PLD/Autotaxin Pathway 
 
Autotaxin (ATX) was identified as an autocrine tumor cell motility factor from A2058 
melanoma conditioned medium.15 ATX has lysophospholipase D enzyme activity and is 
responsible for the cleavage of lysophophatidylcholine (LPC) leading to the generation of 
LPA16,17 and CPA.18 ATX is under feedback inhibition by its hydrolysis products LPA, 
CPA, and sphingosine-1-phosphate (S1P).19 Lyso-PLD generates LPA by hydrolyzing 
the phosphodiester bond of lysphospholipids, which are formed by the action of PLA1 
and PLA2 on phospholipids. 
 
 
The Phospholipase A Pathway 
 
LPA is generated from the hydrolysis of phosphatidic acid (PA) at sn-1 or sn-2 position 
by PLA1 or PLA2 , respectively. Activation of platelets results in LPA production by 
different mechanisms. Only about 10% of the total serum LPA is contributed by 
hydrolysis of PA by PLA enzymes. PLA enzymes can also convert a varitety of 
phospholipids, e.g., phosphatidylcholine (PC), phosphatidylethanolamine (PE), 
Phosphatidylserine (PS) with a varying specificity to their corresponding lysolipid forms. 
Upon activation, platelets release PLA1 and PLA2 enzymes that generate a de novo pool 
of lysophospholipids from phospholipids, which serve as substrates for lyso-PLD to 
generate LPA.20 Thus the rate-limiting step in LPA generation in blood is not the 
hydrolysis of phosphodisterase bond by lyso-PLD, but the release of PLA1 and PLA2 
enzymes from platelets and de novo generation of a new lysophospholipids pool. 
Microvesicles, shed by activated inflammatory cells, have altered membrane asymmetry 
resulting in accumulation of PA in the outer leaflet of plasma membrane. Secretory or 
type II PLA2 released from these microvesicles is involved in LPA production by 
generating the corresponding lyso-lipids from PE and PC, which upon lyso-PLD-
mediated hydrolysis result in LPA production. Phospholipase D (PLD) may also be 
involved in PLA mediated PA-derived LPA production by generating the PA from 
phospholipids including PC, PE and PS. 
 
 
Mild Oxidation of Low Density Lipoprotein 
 
Mild oxidation of low density lipoprotein (mox LDL) generates LPA resulting in its 
thrombotic and artherogenic actions. LPA also elicits platelet aggregation and intra-
arterial thrombus formation after the rupture of lipid rich atherosclerotic plaques.21 
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Intracellular Generation of LPA 
 
 
The Glycerophosphate Acyl Transferase (GPAT) Pathway 
 
LPA is a key intermediate in the synthesis of phospholipids and triglycerides in many cell 
types. GPAT which is located in the endoplasmic reticulum and in the mitochondria, 
catalyzes, the acylation of glycerol 3-phosphate generating LPA.  
 
 
The Action of Acyl Glycerol Kinase  
 
Phosphorylation of monoacylglycerol (MAG) by MAGK in the inner leaflet of the 
plasma membrane results in LPA formation. MAGK has also been proposed to be 
involved in the formation of arachidonyl-LPA in platelets. Similar to GPAT pathway, 
LPA produced by MAGK pathway also contributes to the intracellular LPA pool. 
 
 
Reduction of Acyl Dihydroxy Acetone Phosphate  
 
Intracellular LPA can also be synthesized by reduction of acyl DHAP in peroxisomes. 
Pancreatic islets when exposed to high glycose concentrations are shown to form LPA 
utilizing this pathway. 
 
 
LPA Degradation 
 
The degradation of LPA occurs in three different pathways as discussed below.  
 
 
LPA Degradation by Phosphatases 
 
LPA is dephosphorylated to form MAG by phosphatases that belong to phosphatidate 
phosphatases type2 (PAP-2) that are also known as lipid phosphate phospohydrolase 
(LPP).22,23 There are four isoforms of LPP family, which includes LPP1, LPP1α, LPP2 
and LPP3 that have been cloned and characterized in mammals.24-26 Although all of these 
isoforms dephosphorylate LPA and other phospholipids, they show different selectivites 
for the lipid substrate in vitro. LPP1 has been shown to have the rank order preference of 
LPA > PA > sphingosine 1-phosphate (S1P) > ceramide 1-phosphate (C1P).26,27 LPP2 is 
selective for PA > C1P > LPA > S1P and LPP3 shows similar activity towards PA and 
LPA with a preference over C15 and S1P.26 LPP1 did not show any stereo selectivity and 
acyl group selectivity over alkyl group in LPA analogs.28 The differential tissue 
distribution and substrate selectivities of LPP isoforms may be significantly affecting the 
biological actions of LPA.  
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LPA Degradation by Lysophospholipases 
 
The second pathway of LPA degradation involves the removal of the long chain fatty-
acyl group of LPA so as to convert LPA to glycerophosphate. Two distinct 
lysophospholipases with specificity towards LPA and LPC have been characterized 
currently.29-32 
 
 
LPA Degradation by Acyltranferases 
 
LPA acyltransferases (LPAAT), also known as 1-acylglycerol 3-phosphate 
acyltransferases (AGPAT), catalyzes the acylation of LPA to form PA.33-35 LPAAT 
enzymes include transmembrane family of proteins. The LPAAT family enzymes has 
seven enzymes that have been characterized till date, including, LPAATα, LPAATβ, 
LPAATγ, LPAATδ, LPAATε, LPAATζ, LPAATη.36,37 For the synthesis of PA from 
LPA, two LPAATs (LPAAT1, and 2) have been cloned and characterized. Namely, 
human LPAAT1 (also called AGPAT1 or LPAATα) and human LPAAT2 (also called 
AGPAT2 or LPAATβ). Human LPAAT1 shows higher activity towards 14:0-, 16:0-, and 
18:2-CoAs, while human LPAAT2 prefers 20:4-CoA over 16:0-or 18:0-CoA.37 
 
 
LPA Receptors 
 
Extracellular LPA exerts its wide array of pharmacological effects through the activation 
of G-protein coupled receptors (GPCRS). In addition to the GPCR’s, LPA also activates 
the nuclear transcription factor, peroxisome proliferator activated receptor γ (PPARγ). 
 
 
LPA Plasma Membrane GPCR 
 
LPA GPCR’s have been acknowledged to be in two distinct gene families, namely, the 
endothelial gene (EDG) family and the P2Y gene cluster.38 The EDG family encodes 
GPCR’s specific to LPA and Sphingosine 1 phosphate (S1P).38 The first three LPA 
receptors, viz. LPA1, LPA2 and LPA3 belong to the EDG family. These three receptors 
share 45-56% of their amino acid identity.38,39 Whereas, LPA4, LPA5, GPR87, P2Y5 and 
P2Y10 are the members of the P2Y gene cluster.38 LPA4 and LPA5 share 20-24% amino 
acid identity.40 
 
LPA1-2 are ubiquitously present. LPA is their endogeneous ligand and activator. 
LPA1/EDG2/vzg-1 was the first reported LPA receptor.41,42 LPA1 mediates its 
intracellular responses through the interaction with Gi/o, Gq and G12/13 proteins.43 The 
cellular effects mediated by LPA1 include the inhibition of adenyl cyclase,41 stimulation 
of Rho signaling,44 activation of serum response factor,45 Phospholipase C (PLC), ERK, 
Akt, Rac, DNA synthesis, Ca2 + signaling.46 LPA2 shares 60% amino acid identity with 
LPA1.47 Analogous to LPA1, LPA2 also is associated with Gi/o, Gq and G12/13 proteins that 
mediate inhibition of adenyl cyclase, stimulation of Rho signaling, activation of PLC, 
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ERK, Akt and intracellular Ca2 + signaling.48,49 LPA3 shows approximately 50% amino 
acid sequence homology with LPA1 and LPA2. LPA3 is associated with Gi/o and Gq  
proteins that mediate activation of PLC, ERK and Ca2 + signaling and LPA3 has also been 
reported to stimulate and inhibit the adenyl cyclase.43,49 
 
LPA4 shows a wide tissue distribution with high levels in ovary, uterus and placenta.40 It 
mediates intracellular responses via Gq and G12/13 proteins that mediate the activation of 
cyclic AMP.50-52 LPA5 shows high expression in the CD8 + lymphocytes, B cells, platelets 
and the dorsal root ganglion cells and is associated with Gq and mediates the activation of 
cAMP.51-53 Squamous cell carcinomas showed a high expression of GPR87.54-56 GPR87 
mediates cellular responses via Gq and G16 proteins. P2Y5 was found to be expressed in 
Henley and Huxley layers of the scalp hair follicles.57 The cellular responses are 
mediated through Gq, Gs and G12/13 by stimulating cAMP.58 P2Y10 was detected in uterus, 
brain, prostate, lung, placenta, skeletal muscles and brain cells and it is associated with 
the RhoA-ROCK signaling axis mediated through Gq and G16.59 
 
 
PPARγ: An Intracellular Receptor of LPA  
 
Peroxisome proliferator activated receptor γ (PPAR γ) is a nuclear receptor for LPA that 
exhibits its activity intracellularly.60 The PPAR family consists of three members PPARα, 
PPARβ/δ and PPARγ.61 LPA induced activation of PPARγ appears to be an important 
step in the regulation of adipogenesis, macrophage function, neointima formation, and 
atherogenesis.38,62  
 
 
Importance of LPA in Physiological Systems 
 
 
LPA in Malignant Neoplasm 
 
LPA mediates a plethora of physiological and pathological activities via interactions with 
a series of high affinity G protein-coupled receptors (GPCR). LPA is a mitogen, motogen 
and an anti-apoptotic agent.38 Both LPA receptor family members and autotaxin 
(ATX/LysoPLD), the primary LPA-producing enzyme, are aberrantly expressed in many 
cancers. The ATX-LPA receptor axis plays a causal role in tumorigenesis and cancer-
related inflammation, further validating the ATX-LPA receptor axis as a rich therapeutic 
target in cancer.38,63 LPA conveys resistance to chemo and radiation therapy through its 
anti-apoptotic action.64-66 The LPA2 receptor is implicated in chemoresistance.65,67-70 
Siva-1 also binds and sequesters the anti-apoptotic BCL-XL protein and promotes the 
progression of apoptosis via the mitochondrial pathway.38,71-73 LPA induced molecular 
complex between LPA2 and Siva-1 fosters the anti-apoptotic effect of LPA.38 LPA is 
responsible for the upregulation of matrix metalloprotease (MMP) production, which in 
turn promotes the proliferation of cancer cells and invasion.38,74-76  
 
 6 
LPA in Nervous System 
 
LPA and its receptors are involved in maintaining the normal physiology of the nervous 
system. Both LPA1 and LAP2 are expressed in the central nervous system.77 LPA is 
important in myelination and Schwann cell survival.38,78-81 LPA has also been suggested 
to modulate the blood-brain barrier (BBB) by enhancing the tight junction permeability in 
brain-derived endothelial cells.82 LPA boosts the formation of cortical folds that leads to 
the development of gyri in the cerebral cortex.38,83-85 LPA is involved in mediating 
neuropathic pain.38 When LPC is injected intrathecally, it has been proven to evoke 
neuropathic pain and result in de-myelination.38,86,87 These effects of LPA require ATX 
and the responsible bioactive compound is LPA which is generated from LPC hydrolysis 
by ATX.86,88 
 
 
LPA in Cardiovascular System 
 
LPA seems to be playing a vital role in thrombogenesis and atherogenesis.89,90 It has been 
identified in mox-LDL, human atherosclerotic plaques and the supernatants of activated 
platelets.20,90 LPA and mox-LDL mediates platelets shape change and platelet 
aggregation in isolated platelets.89 LPA that is released upon the rupture of unstable 
atherosclerotic plaques in vivo, encounter platelets circulating in the blood and cause 
platelet shape change and aggregation, ultimately leading to the formation of 
thrombus.21,89 In addition to the thrombogenic activity, LPA also has atherogenic 
properties. LPA increases the endothelial permeability and monocyte adhesion to the 
endothelium.90-92 LPA also increases the vascular tone of the vascular smooth muscle 
cells in many animal models.90,93,94 LPA generation is an important target for 
manipulating pathological angiogenesis and thrombosis.38 
 
 
LPA in Organ Fibrosis 
 
LPA has a mitogenic effect on fibroblasts38,95,96 and it also increases connective tissue 
growth factor production contributing to tissue fibrosis.38,97-99 LPA has been implicated in 
renal,38,100 hepatic,38,101,102 and pulmonary fibrosis.38,103,104 In several pharmacological 
models, the inhibition of LPA1 receptor inhibits the progression of fibrosis.38 LPA1 
receptor antagonist based therapies would provide a therapeutic management of 
fibrosis.38,100,103 
 
 
LPA in Bone Metabolism 
 
LPA has also been identified as a mitogen for osteoblasts.38,105-108 It has been shown to 
prevent osteoblasts apoptosis109 and stimulate alkaline phosphatase expression110 and cell 
migration.38 LPA is also shown to be a potent stimulator of dendrite outgrowth, which is 
inhibited by LPA1/LPA3 antagonist Ki16425 and pertusis toxin.38,111 Pharmacological 
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manipulation of LPA receptors may pave a way to preventing bone loss and bone 
metastasis of cancers.38 
 
 
LPA in Immunity  
 
The cellular markers of immune responses like, T lymphocytes,112 B cells,113-115 
eosinophils,116 neutrophils,117 macrophages,118 mast cells,119 and dendritic cells,120-122 
express LPA receptors.38 Natural killer cells act in response to LPA by chemotaxis and 
increased production of IFNγ.38,123-125 LPA differentially regulates the development of 
CD1 dendritic cells. CD-1 molecules are involved in the T cell recognition of self 
lipids.38,126-128 CD1 restricted T cells mediate defence mechanisms and pro-inflammatory 
responses in case of autoimmune diseases like lupus erythematodes,129 multiple 
sclerosis130 and autoimmune thyroditis131 in host.38 
 
 
Physiological and Pathological Role of Autotaxin  
 
Autotaxin (ATX) was identified as an autocrine tumor cell motility factor from A2058 
melanoma conditioned medium.15 ATX has lysophospholipase D enzyme activity and is 
responsible for the cleavage of lysophophatidylcholine (LPC) leading to the generation of 
LPA16,17 and CPA.18 High levels of autotaxin are generated in a wide variety of 
metastatic human tumor cell lines including human teratocarcinoma,132 
hepatocellularcarcinoma,133 metastatic breast cancer,134 ovariancancer,135 thyroid 
carcinoma,136 prostate cancer,137 follicular lymphoma138 and glioblastomamultiforme.139 
ATX plays an important role in the chemotherapeutic resistance of breast140 and ovarian 
cancer cells.135 ATX is under feedback inhibition by its hydrolysis products LPA, CPA, 
and sphingosine-1-phosphate (S1P).19 Lyso-PLD generates LPA by hydrolyzing the 
phosphodiester bond of lysphospholipids, which are formed by the action of PLA1 and 
PLA2 on phospholipids. Two groups independently reported purifying lyso-PLD, which 
unexpectedly is identical to autotaxin (ATX), a 125 kDa glycoprotein that stimulates 
tumor cell motility. ATX was originally isolated from human melanoma cells and was 
implicated in the metastatic and invasive potential of cancer cells and angiogenesis in 
various cell types. ATX-deficient mice die at embryonic day 9.5 with profound vascular 
defects in the yolk sac and embryo. 
 
Molecular cloning of ATX revealed that ATX/Lyso-PLD is a member of nucleotide 
pyrophosphatase/phosphodiesterase (NPP) family, which includes NPP1, NPP2, NPP3, 
NPP4, NPP5, NPP6, and NPP7. ATX possesses NPP ativity to hydrolyze nucleosides 
such as ATP and ADP generating nucleoside 5’–monophosphate and ATX is categorized 
as NPP-2. NPP-2 is the only PLD in NPP family and it catalyzes production of 
lysophosphatidic acid (LPA) in extracellular fluids. NPP-1, 2 and 3 catalyse the 
hydrolysis of pyrophoshphate and phosphodiester bonds in a two step mechanism in 
which two essential divalent metal ions are required for the formation of a 
nucleotidylated active site threonine intermediate and the subsequent release of 
nucleoside 5’-mono-phosphate. NPP members have been localized in different cellular 
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compartments and are differentially targeting the plasma membranes of polarized cells, 
suggesting specific roles of NPP’s in cells and tissues. Human NPP-1 is highly expressed 
in bone and cartilage cells with intermediate expression in heart,liver, placenta and 
testis.141 NPP-3 promotes differentiation and invasion of glial cells.The function of 
NPP-4 and NPP-5 is unknown. NPP-6 and NPP-7 are choline specific phospholipase C. 
NPP-6 converts LPC to monoacylglycerol and phosphocholine and also hydrolyses 
sphingophosphorylcholine (SPC) and glycerophosphorylcholine (GPC). NPP-7 is 
identical to alkaline sphingomyelinase (alk-Smase) which hydrolyzes sphingomyelin to 
generate ceramide in the intestinal tract protecting the mucosa of inflammation and 
tumorogenesis.142 
 
As described earlier, there is a growing body of evidence that links ATX to cancer. ATX 
boosts aggressiveness, metastasis, angiogenesis in malignancies and also is proven to 
increase the resistance to chemotherapeutic agents. ATX-LPA axis is a promising 
therapeutic target for the management of cancer. 
 
Chapter 2 includes the stereospecific synthesis of 3-CCPA. Cyclic phosphatidic acid 
(CPA) is a naturally occurring analog of lysophosphatidic acid (LPA) in which the sn-2 
hydroxy group forms a 5-membered ring with the sn-3 phosphate. Here we describe the 
synthesis of R-3-CCPA and S-3-CCPA along with their pharmacological properties as 
inhibitors of lysophospholipase D/autotaxin, agonists of the LPA5 GPCR, and blockers of 
lung metastasis of B16-F10 melanoma cells in a C57BL/6 mouse model. S-3CCPA was 
significantly more efficacious in the activation of LPA5 compared to the R stereoisomer. 
In contrast, no stereoselective differences were found between the two isomers toward 
the inhibition of autotaxin or lung metastasis of B16-F10 melanoma cells in vivo. These 
results extend the potential utility of these compounds as potential lead compounds 
warranting evaluation as cancer therapeutics. 
 
Chapter 3 focuses on discovery of a potent ATX inhibitor. Autotaxin (ATX, NPP2) is a 
member of the nucleotide pyrophosphate phosphodiesterase enzyme family. ATX 
catalyzes the hydrolytic cleavage of lysophosphatidylcholine (LPC) via a 
lysophospholipase D activity which leads to the generation of the growth factor-like lipid 
mediator lysophosphatidic acid (LPA). ATX is highly upregulated in metastatic and 
chemotherapy-resistant carcinomas and represents a potential target to mediate cancer 
invasion and metastasis. Here we report the synthesis and pharmacological 
characterization of non-lipid inhibitors of ATX based on the [4-(tetradecanoylamino) 
benzyl] phosphonic acid scaffold that was previously found to lack sufficient stability in 
cellular systems. The new 4-substituted benzyl phosphonic acid and 6-substituted 
naphthalene-2yl-methyl phosphonic acid analogs blocked ATX with Ki values in the low-
micromolar-nanomolar range through a mixed-mode mechanism of inhibition. None of 
the compounds tested inhibited the activity of related enzymes (NPP6 and NPP7). In 
addition, the compounds were evaluated as agonists or antagonists of seven LPA receptor 
subtypes. Analogs 22 and 30b, the two most potent ATX inhibitors, dose-dependently 
inhibited the invasion of MM1 hepatoma cells across murine mesothelial and human 
vascular endothelial monolayers in vitro. Likewise, compounds 22 and 30b significantly 
reduced lung metastasis of B16-F10 syngeneic mouse melanoma in a post-inoculation 
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treatment paradigm. The described 4-substituted benzyl phosphonic acids and 
6-substituted naphthalene-2yl-methyl phosphonic acids represent new lead compounds 
that effectively inhibit the ATX-LPA-LPA receptor axis both in vitro and in vivo. 
 
Chapter 4 focuses on the discovery of non-lipid LPA agents by screening the GRI 
compound library and ultimately identifying a lead. 
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Lysophosphatidic acid (LPA) is a pleiotrophic phospholipid growth factor with multiple 
roles in cancer metastasis and progression.134 LPA elicits numerous biological effects 
including the promotion of cellular survival, mitogenesis, angiogenesis, migration, and 
cancer invasion that are mediated, at least in part, by specific cell surface G protein-
coupled receptors (GPCR) and intracellular targets that include the nuclear hormone 
receptor peroxisome proliferator-activated receptor (PPARγ).1 Cylic-phosphatidic acid 
(1-acyl-2,3-glycerophosphate, CPA) is a naturally occurring analog of LPA in which the 
sn-2 hydroxy group forms a 5-membered ring with the sn-3 phosphate.7 CPA affects 
numerous cellular functions, including inhibition of cell cycle progression, induction of 
stress fiber formation, inhibition of tumor cell invasion and metastasis, and regulation of 
differentiation and survival of neuronal cells.10 CPA is a weak agonist of the LPA1 and 
LPA2 GPCR.9 Substitution of the sn-2 or sn-3 oxygen with a methylene in CPA yields 
carba-CPA (CCPA), a stabilized analog of CPA.144 Previous work has shown that 
3-CCPA does not activate the LPA1-4 GPCR9 but is a weak agonist of LPA5.52 
 
Autotaxin (ATX) was initially identified as an autocrine tumor cell motility factor from 
melanoma cell conditioned medium.15ATX has lysophospholipase D enzyme activity and 
is responsible for the hydrolysis of lysophophatidylcholine leading to the generation of 
LPA16,17and CPA.145 While ATX can also produce sphingosine-1-phosphate (S1P) in 
vitro, it does not appear to contribute in a major way to S1P production in vivo. High 
levels of autotaxin are generated by a wide variety of metastatic human tumor cell lines 
including human teratocarcinoma,132 hepatocellularcarcinoma,133 metastatic breast 
cancer,134 ovariancancer,135 thyroid carcinoma,136 prostate cancer,137 follicular 
lymphoma138 and glioblastomamultiforme.139 ATX also plays an important role in the 
chemotherapeutic resistance of breast140 and ovarian cancer cells135 to chemotherapeutic 
agents. ATX is under feedback inhibition by its hydrolytic products LPA, CPA, and 
sphingosine-1-phosphate (S1P).19 Racemic 2-CCPA and 3-CCPA are potent inhibitors of 
ATX activity and 3-CCPA has been shown to reduce lung metastasis of B16-F10 
melanoma cells injected intravenously into C57BL/6 mice.9 We hypothesized that after 
the synthesis of stereochemically pure isomers 18:1 3-CCPA we would be able to 
distinguish between differences in the pharmacological activities of the two steroisomers. 
To further explore the therapeutic utility of 3-CCPA, we synthesized and characterized  
both the R-3-CCPA and S-3-CCPA.The approach used for the synthesis of the two 
stereoisomers of 3-CCPA is shown in Scheme 2.1. Dimethylphosphonate derivatives 2R 
 
 
 
* This chapter is adapted with permission from Elsevier publishing services. Gupte, R.; 
Siddam, A.; Lu, Y.; Li, W.; Fujiwara, Y.; Panupinthu, N.; Pham, T. C.; Baker, D. L.; 
Parrill, A. L.; Gotoh, M.; Murakami-Murofushi, K.; Kobayashi, S.; Mills, G. B.; Tigyi, 
G.; Miller, D. D. Synthesis and pharmacological evaluation of the stereoisomers of 
3-carba cyclic-phosphatidic acid. Bioorg. Med. Chem. Lett. 2010, 20, 7525-7528. 
Chapter 2. Synthesis and Pharmacological Evaluation of the Stereoisomers of 
3-Carba Cyclic-Phosphatidic Acid* 
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Scheme 2.1. Synthesis of 18:1 R-3-CCPA and S-3-CCPA. 
Reagents and conditions: (a)(i) THF, n-BuLi (2.5M in hexane),-78°C, 0.5hr; (ii) R-
Benzyl glycidyl ether (R)/S-Benzyl glycidyl ether (S); (iii) THF,BF3OEt2,-78°C, 2hr; 
(iv)-20°C, 2hr, 68%; (b) PPTS, Toluene, Reflux, 5hr, 65%; (c) H2, Pd(OH)2/C, MeOH, 
82.5%; (d) C17H33COOH, DMAP, DIC, DCM,18hr, 78%; (e) TMSBr,CH2Cl2, 1hr, 53%; 
(f) 0.05M NaOH. 
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and 2S were generated from compound 1 using n-butyllithium, BF3 etherate and either 
the R-or S-isomer of benzylglycidyl ether. The corresponding 3-carbacyclic analogs 3R 
and 3S resulted from treatment with pyridinium p-toluenesulfonate (PPTS). Following 
benzyl group deprotection by hydrogenation,the resulting alcohols 4R and 4S were 
converted to oleoyl esters 5R and 5S using N,N’-diisopropylcarbodiimide (DIC) and 
dimethylaminopyridine (DMAP). Final products R-3-CCPA and S-3-CCPA were 
prepared by methyl group deprotection and conversion to the corresponding sodium salts 
using TMSBr and dilute NaOH, respectively. Optical rotations were determined by 
dissolving the compounds in methanol, to be  + 7.3° for R-3-CCPA and for S-3-CCPA, 
the optical rotation was -7.9°. Each compound was purified by silica gel column 
chromatography and verified by mass spectrometry, NMR and HRMS. 
 
Compounds 3R and 3S were also converted to the benzyl ether derivatives of 3-CCPA as 
shown in Scheme 2.2. However in the Autotaxin inhibition assay, Compound 8R and 8S 
failed to show any activity. 
 
 
Biology 
 
Compounds R-3-CCPA and S-3-CCPA were examined for their ability to block ATX-
mediated hydrolysis of FS-3(Echelon Biosciences, Inc. Salt Lake City, UT) using a 
fluorescence resonance energy transfer-based assay.146 Recombinant ATX (25 nmol) in 
the presence of various concentrations of R-3-CCPA, S-3-CCPA, or LPA 18:1 (positive 
control) in assay buffer consisting of 1 mM MgCl2, 1 mM CaCl2, 3 mM KCl, 140 mM 
NaCl, 50 mM Tris-HCl, pH 8.0 and 15 μM fatty acid free BSA was added to FS-3 (final 
concentration 1 µM).The ATX inhibition assay was carried out in Dr.Tigyis Laboratory. 
Assays were performed in white wall 96-well plates (Corning Inc., Corning, NY) and the 
fluorescence (excitation 485 nm, emission 538 nm) was measured at the beginning and 
after 2 hours of incubation at 37°C using a FLEX stationII plate reader (Molecular 
Devices, Sunnyvale, CA). Data were normalized to the corresponding vehicle control, 
and the mean ± standard deviation of triplicate wells was used to calculate ATX activity 
as per cent of vehicle control (Figure 2.1). 
 
The dose response-relationship of ATX inhibition showed little difference between the 
R-3-CCPA, S-3-CCPA or the racemate. However, R-3-CCPA was approximately 2 fold 
more potent in this assay than S-3-CCPA. The kinetic mechanism by which R-3-CCPA 
and S-3-CCPA inhibited recombinant ATX-mediated hydrolysis of FS-3 were 
determined by varying the concentration of the substrate (FS-3, ranging from 0.3 to 20 
μM) in the presence of three concentrations of each inhibitor (0, 0.5 and 2 times the IC50). 
Simultaneous non-linear regression using WinNonLin ® 6.1 (Pharsight, Mountain View, 
CA) was used to fit experimental data and calculate Ki and Ki' using the Michaelis-
Menten equations for competitive, uncompetitive, mixed-mode, and non-competitive 
inhibition as we have described in recent work.147-149 Mechanism of inhibition was 
assigned based on the lowest averaged percent residuals for each mechanism derived 
from curve fitting. Using this procedure R-3-CCPA and S-3-CCPA were determined to 
be mixed mode ATX inhibitors with Ki values of 0.8 and 1.6 µM, respectively.  
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Scheme 2.2. Synthesis of 8R and 8S Analogs. 
Reagents and conditions: (a)TMSBr,CH2Cl2, 1hr, 53 %; (b) 0.05M NaOH. 
 
 
 
 
 
 
Figure 2.1. Dose Response Relationship of ATX Inhibition by LPA, R-3-CCPA, S-3-
CCPA and Racemic-3-CCPA Analogs. 
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The mechanism of inhibition study was performed by Dr.Bakers group at the University 
of Memphis. The lack of ligand stereospecificity of the LPA1, LPA2, and LPA3 receptors 
has been published previously28 but no information of stereoselective ligand acitvitaion  
for LPA5 is currently available at the present time. Racemic-3-CCPA has previously been 
shown to be an agonist of the LPA5 GPCR.52 Here we compared the dose-response 
curves of LPA5 activation for R-3-CCPA and S-3-CCPA with that of the racemate. These 
experiments were performed in B103 cells stably expressing LPA5. Wild type B103 cells 
do not produce Ca2 + transients in response to LPA and are widely used as a host cell for 
LPA receptor expression studies. B103-LPA5 cells were loaded with Fura-2AM for 30 
min in modified Krebs buffer containing 2% (v/v) pluronic acid, rinsed with Krebs 
buffer, and changes in the intracellular Ca2 + concentration were monitored by 
determining the ratio of emitted light intensities at 520 nm in response to excitation at 
340 and 380 nm using a FLEX station II plate reader (Molecular Devices, Sunnyvale, 
CA).150 The Activity of the sterioisomers on LPA5 was determined in Dr.Tigyi’s 
Laboratory. Compound S-3-CCPA showed significantly higher (p < 0.05) efficacy than 
did R-3-CCPA for LPA5-mediated calcium mobilization at concentrations above 1 µM 
(Figure 2.2). Thus, the LPA5 receptor shows a slight stereoselectivity for the S-over the 
R-stereoisomer which contrasts the weak preference ( ~ 2-fold) shown by ATX for the 
R-isomer. 
 
It has been previously shown that racemic 3-CCPA inhibited lung metastasis of B16-F10 
melanoma in a mice model. To extend this observation, the stereoisomers were 
characterized in this model.9,10 This in vivo testing was carried out at the M.D Anderson  
Cancer Center by Dr. Mills’s group. Eight-week-old female C57Bl/6 mice were 
 
  
 
 
 
Figure 2.2. Dose-Response Relationship of LPA5 Mediated. 
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inoculated with 5 x 104melanoma cells via the tail vein and divided randomly into 4 
groups. The groups then received either saline vehicle, R-3-CCPA, S-3-CCPA, or 
racemate (at 0.5 mg/kg intraperitoneally) 30 min after the B16-F10 inoculation and daily 
for an additional 10 days. Animals in all groups were monitored for an additional 10 days 
without further treatments. On day 21, all mice were sacrificed and lungs were dissected, 
fixed with formalin and the numbers of black melanoma nodules on the lung surface were 
counted in each sample (Figure 2.3). All 3-CCPA treated groups (R-3-CCPA, S-3-CCPA 
and Racemic-3-CCPA) significantly reduced the number of lung metastases compared to 
the vehicle treated group. However, no statistically significant differences were found 
between the 3-CCPA treated groups using ANOVA followed by Newman-Keuls multiple 
comparison test. 
 
 
Chemistry 
 
All starting materials, reagents and solvents were obtained from commercial suppliers 
and were used without further purification. Reactions were performed under an inert 
atmosphere of nitrogen, unless otherwise specified. Routine thin-layer chromatography 
(TLC) was performed on silica gel plates (Analtech, Inc., 250 microns). Flash 
chromatography was conducted on silica gel (Merck, grade 60, 230-400 mesh). 1H NMR 
spectra were recorded on a Bruker ARX 300 spectrometer (300 MHz) or Varian 
spectrometer (500MHz) using DMSO-d6 and CDCl3 as solvents, and spectral data were 
consistent with assigned structures. Chemical shift values were reported as parts per 
million (δ), coupling constants (J) are given in Hz, and splitting patterns are designated as 
follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet. Optical rotation was 
measured on AUTOPOL III instrument at 25°C and at (wavelength) λ = 589. Mass  
spectra were collected on a Bruker ESQUIRE electrospray ionization /ion (ESI) trap 
instrument in the positive and negative modes. High-resolution mass (HRMS) 
measurements were obtained using a Micromass Q-TOF2 mass spectrometer. 
 
General procedure for the synthesis of 2R/2S: To a solution of methylphosphonic acid 
dimethyl ester (2.6 ml, 24.0 mmol) in THF (40 ml)in a clean dry flask, was added 
n-butyllithium (2.5 M solution in hexane) (14.5 ml, 24.0 mmol) at −78°C, and the 
reaction mixture was stirred for 0.5 h at −78°C. To this mixture was added BF3 etherate 
(3.04 ml, 24.0 mmol), followed by a solution of (R)-benzylglycidyl ether/(S)-
benzylglycidyl ether (1.83 ml, 12.0 mmol) in THF (10 ml). The reaction mixture was 
stirred for 2 h at −78°C and then warmed to −20°C and stirred for 2 h. The reaction 
mixture was quenched by the addition of saturated NH4Cl, extracted with ethylacetate 
(100 ml × 3) and washed with saturated NaCl (50 ml). The combined organic layer was 
dried over anhydrous MgSO4, and the solvent was removed under reduced pressure. The 
residue was purified by column chromatography on silica gel (eluted with CHCl3/MeOH 
(30:1)) to give compound 2R or 2S (66%-68%). 
 
2R: 1H NMR (500MHz, DMSO) δ = 7.350 (5H, m); 4.819-4.809 (1H, d, J = 5); 4.482 
(2h, s); 3.614-3.600 (6H, d, J = 7 Hz); 3.376-3.269 (2H, m); 1.187-1.450 (4H, m). MS 
(ESI) m/z 311.0 [M + Na] + . 
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Figure 2.3. Lack of Stereoselectivity in Lung Metastasis of B16-F10 Melanoma Cells 
by R-3-CCPA, S-3-CCPA and Racemic-3-CCPA Analogs in a Mouse Model. 
A) Representative images show fixed intrathoracic organs including lung lobules with 
visible nodules on the surfaces in black. Total numbers of nodules were reduced in 
samples treated with 7R, 7S or racemate compared to vehicle. Scale bar is 0.5 cm. B) 
Lung nodules of B16-F10 melanoma cells were quantified. The number of lung nodules 
was significantly decreased in groups treated with R-3-CCPA, S-3-CCPA, and the 
Racemic-3-CCPA compared to vehicle. However, no statistically significant differences 
were found either between the stereoisomers or the racemate. Data represent the 
mean.±.SEM, n  = 6-8 mice. * p < 0.05 compared to vehicle analyzed by one-way 
ANOVA followed by Newman-Keuls multiple comparison test. 
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2S: 1H NMR (500MHz, DMSO) δ = 7.36-7.282 (5H, m); 4.819-4.809 (1H, d, J = 5); 
4.482 (2h, s); 3.614-3.600 (6H, d, J = 7Hz); 3.376-3.269 (2H, m); 1.187-1.450 (4H, m). 
MS (ESI) m/z 311.0 [M + Na]. 
 
General procedure for the synthesis of 3R/3S: To a solution of 2R/2S (440 mg, 1.53 
mmol) in toluene (20 ml) was added a pyridinium p-toluenesulfonate (1.15 g, 4.58 
mmol), and the reaction mixture was heated at reflux for 3 h. The mixture was cooled and 
diluted with ethyl acetate (100 ml). The mixture was washed with saturated NaCl (70 ml), 
and the organic layer was dried over anhydrous MgSO4. The solvent was removed under 
reduced pressure, and the residue was purified by column chromatography on silica gel 
(300 Mesh) (eluted with CHCl3/MeOH (30:1)) to give 3R/3S (55%-58%). 
 
3R: 1H NMR (300MHz, CDCl3) δ = 7.363-7.303 (5H, m); 4.608 (2h, s); 4.419-4.408 (1H, 
p); 3.816-3.779 (3H, d, J = 11.1Hz); 3.633-3.588 (2H, m); 2.218-1.889 (4H, m). MS 
(ESI) m/z 257.0 [M + H]; m/z 279.0 [M + Na]. 
 
3S: 1H NMR (500MHz, CDCl3) δ = 7.378-7.312 (5H, m); 4.619 (2h, s); 4.419-4.408 (1H, 
p); 3.820-3.798 (3H, d, J = 11Hz); 3.628-3.619 (2H, m); 2.325-1.733 (4H, m). MS (ESI) 
m/z 257.0 [M + H]; m/z 279.0 [M + Na]. 
 
General procedure for the synthesis of 4R/4S: To a solution of 3R/3S (252 mg, 0.98 
mmol) in ethanol (5 ml) was added 20% Pd (OH)2/C (25 mg), and the mixture was stirred 
under H2 at room temperature for 1 day. The catalyst was removed by filtration and the 
filtrate was evaporated under reduced pressure. The residue was purified by column 
chromatography on silica gel (eluted with CHCl3/MeOH (20:1)) to give 4R/4S (143 mg, 
0.86 mmol, 88%). 
 
4R: 1H NMR (300MHz, CDCl3) δ = 4.54-4.3 (1H, m); 3.824-3.795 (3H, d, J = 8.7Hz); 
3.639-3.623 (2H, m); 2.4-1.951 (4H, m). MS (ESI) m/z 188.9 [M + Na]. 
 
4S: 1H NMR (500MHz, CDCl3) δ = 4.509-4.473 (1H, m); 3.825-3.803 (3H, d, J = 11Hz); 
3.649-3.602 (2H, m); 2.640 (1H,s); 2.310-1.900 (4H, m). MS (ESI) m/z 188.9 [M + Na]. 
 
General procedure for the synthesis of 5R/5S: To a solution of palmitic acid (0.288 g, 
1.018mmol) in dry CH2Cl2 (5ml), was added diisopropylcarbodiimide (0.154gm, 1.223 
mmol) and was allowed to stir for 10 minutes. To this reaction mixture, 
dimethylaminopyridine (DMAP) (0.031gm, 0.254 mmol), triethylamine (0.0857gm, 
0.848 mmol) 4R/4S (0.140g, 0.848mmol) in CH2Cl2 (1 ml) were added successively at 
0°C. The reaction mixture was stirred for 1 day at room temperature. The reaction 
mixture was filtered, diluted with dichloromethane (50 ml) and washed by saturated NaCl 
(20 ml). The organic layer was dried over anhydrous MgSO4 and evaporated under 
reduced pressure. The residue was purified by column chromatography on silica gel 
(eluted with CHCl3/MeOH (40:1)) to give 5R/5S (0.331gm, 77%). 
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5R: 1H NMR (300MHz, CDCl3) δ = 5.366-5.318 (2H, m); 4.569-4.534 (1H, m); 
4.262-4.098 (2H, m); 3.804-3.782 (3H, d, J = 11Hz); 2.363 (6H, overlapping protons); 
1.647-1.619 (2H, m); 1.306 (20H,s); 0.880 (3H, t). MS (ESI) m/z 453.4 [M + Na]. 
 
5S: 1H NMR (500MHz, CDCl3) δ = 5.366-5.318 (2H, m); 4.569-4.534 (1H, m); 
4.262-4.098 (2H, m); 3.804-3.782 (3H, d, J = 11Hz); 2.363 (6H, overlapping protons); 
1.647-1.619 (2H, m); 1.166 (20H,s); 0.90 (3H, t). MS (ESI) m/z 453.3 [M + Na]. 
 
General procedure for the synthesis of 6R, 6S, 7R, 7S: To a solution of 5R/5S or 3R/3S 
(1Eq) in CH2Cl2 (1 ml) was added bromotrimethylsilane (TMSBr) (2Eq), and the reaction 
mixture was stirred for 1 h at room temperature. The reaction mixture was condensed 
under reduced pressure, and methanol was added to it. This was stirred again for 30 min, 
Methanol form the reaction mixture was evaporated and the residue was purified by 
column chromatography on silica gel (eluted with CHCl3/MeOH (10:1)) to give 6R/6S or 
7R/7S respectively, and were isolated as pure products and immediately converted to 
sodium salts due to poor stability. 
 
Synthesis of R-3-CCPA/ S-3-CCPA: To a solution of 6R/6S (0.066g, 0.159mmol) in 
diethyl ether (2ml) was added 1M NaOH (0.0063g) in water at 0°C. The reaction mixture 
was allowed to stir at room temperature for 30 minutes and a white precipitate was 
observed. The diethyl ether was removed on vacuum and the sample was freeze dried to 
obtain pure compounds R-3-CCPA/S-3-CCPA in quantitative yields. 
 
R-3-CCPA: Optical rotation = + 7.3° (methanol) ; 1H NMR (500MHz, CD3OD) 
δ = 5.366-5.318 (2H, m); 4.2-4.0 (1H, m); 3.65-3.45 (2H, m); 2.2-2.0 (4H, overlapping 
protons); 1.98-1.619 (4H, m, overlapping protons); 1.4-1.2 (20H, s); 0.90 (3H, t). 31P 
NMR (300MHz, CD3OD, Phosphoric acid external standard) δ = 44.110; MS (ESI) m/z 
415.6 [M-H]. HRMS calcd for C22H40O5P; 415.2613 ; found: 415.2612. 
 
S-3-CCPA: Optical rotation = -7.9° (methanol); 1H NMR (500MHz, CD3OD) 
δ = 5.366-5.318 (2H, m); 4.2-4.0 (1H, m); 3.65-3.45 (2H, m); 2.2-2.0 (4H, overlapping 
protons); 1.98-1.619 (4H, m, overlapping protons); 1.4-1.2 (20H,s); 0.90 (3H, t). MS 
(ESI) m/z 415.1 [M-H]. HRMS calcd for C22H40O5P; 415.2613 ; found: 415.2623. 
 
Synthesis of 8R/8S: To a solution of 7R/7S (0.066g, 0.159mmol) in diethyl ether (2ml) 
was added 1M NaOH (0.0063g) in water at 0°C. The reaction mixture was allowed to stir 
at room temperature for 30 minutes and a white precipitate was observed. The diethyl 
ether was removed on vacuum and the sample was freeze dried to obtain pure compounds 
8R/8S in quantitative yields. 
 
8R: 1H NMR (300MHz, CD3OD) δ = 7.340 (5H, m); 4.579 (2H, s); 4.25 (1H, p); 3.55 
(2H, m); 2.3-1.5 (4H, m). 31P NMR  (300MHz, CD3OD, Phosphoric acid external 
standard) δ = 43.535; MS (ESI) m/z 240.9 [M-H]. HRMS calcd for C11H14O4P; 
241.0635; found: 241.0632. 
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8S: 1H NMR (500MHz, CD3OD) δ = 7.378-7.312 (5H, m); 4.61 (2h, s); 4.419-4.408 (1H, 
p); 3.628-3.619 (2H, m); 2.325-1.733 (4H, m). MS (ESI) m/z 240.8 [M-H]; HRMS calcd 
for C11H14O4P; 241.0635; found: 241.0638. 
 
 
Conclusion 
 
In conclusion, we have synthesized pure stereoisomers of 3-CCPA and found that they 
inhibited ATX in vitro and B16-F10 melanoma metastasis in vivo without significant 
stereochemical preference. The lack of stereoselectivity is underlined by the equal 
efficacy of the racemic mixture. Interestingly, at the LPA5 GPCR the S-stereoisomer 
(S-3-CCPA) showed significantly higher efficacy. This is the first indication that the 
LPA5 receptor, unlike the LPA1,2,3 receptors shows stereo-selective activation by CCPA 
ligands. 
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Autotaxin (ATX, NPP2) is member of the nucleotide pyrophosphate phosphodiesterase 
(NPP) enzyme family. ATX catalyzes the hydrolysis of lysophosphatidylcholine (LPC) 
via a lysophospholipase D (LPLD) activity that leads to the generation of the growth 
factor-like, lipid mediator lysophosphatidic acid (LPA).16,17 ATX is a 125 kDa 
glycoprotein, originally isolated from human melanoma cells, that stimulates tumor cell 
motility and has been implicated in the metastatic and invasive properties, as well as 
chemotherapeutic resistance of many carcinomas.56,132-138,140,152 NPP6 and NPP7 are the 
only other known NPP isoforms that utilize lysophospholipids as substrates. However, In 
contrast to ATX, NPP6 and NPP7 act as lysophospholipase C. NPP6 cleaves 
phosphocholine from LPC, sphingosylphosphorylcholine and glycerophosphorylcholine 
to generate monoacylglycerol, sphingosine and glycerol, respectively.153 NPP7, also 
referred to as alkaline sphingomyelinase hydrolyzes sphingomyelin to generate ceramide 
in the intestinal tract but also cleaves phosphocholine from LPC and platelet activating 
factor to generate monoacyl and alkyl-acetyl glycerols.154,155 
 
ATX is required for normal development. Homozygous ATX knockout mice die in utero 
at day 9.5 coinciding with a period of vascular stabilization.156,157 Likewise, ATX plays 
an important role in the development of the nervous system as ATX knockout mice show 
defects in neural tube development.158 LPA is a mitogen, motogen, and anti-apoptotic 
agent, which provides survival advantages to carcinomas that utilize LPA in an autocrine 
or paracrine fashion. Ovarian cancer cells produce high levels of LPA.3,159,160 Copy 
numbers increase in ovarian cancers in chromosomal region 8q24, which contains the 
genes encoding for ATX and the Myc oncogene.161 Euer et.al. found that ATX was 
among the 40 most upregulated genes in highly metastatic cancers.162 Recently it has 
been shown that ectopic expression of ATX in mice leads to mammary intraepithelial 
neoplasia, which develops into invasive and metastatic tumors.163 ATX inhibits 
paclitaxel-induced apoptosis in breast cancer cells,140 and LPA renders ovarian cancer 
cells chemoresistant to cisplatin and adriamycin.65 ATX is also overexpressed in patients 
with recurrent disease after prior treatment with chemotherapy.164 In a genome-wide 
siRNA screen, we identified ATX as a candidate drug-resistance gene in ovarian 
cancer.135 In addition we showed that a lipid-like, small-molecule inhibitor of ATX, 
carba-cyclic-phosphatidic acid increases the sensitivity of resistant ovarian cancer cells to 
paclitaxel treatment.135 
 
 
 
* This chapter is adapted with permission from Wiley-VCH Verlag GmbH & Co. KGaA. 
Gupte, R.; Patil, R.; Liu, J.; Wang, Y.; Lee, S. C.; Fujiwara, Y.; Fells, J.; Bolen, A. L.; 
Emmons-Thompson, K.; Yates, C. R.; Siddam, A.; Panupinthu, N.; Pham, T. C.; Baker, 
D. L.; Parrill, A. L.; Mills, G. B.; Tigyi, G.; Miller, D. D. Benzyl and naphthalene 
methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic 
activity. ChemMedChem. 2011, 6, 922–935. 
Chapter 3. Benzyl and Naphthalene-Methyl Phosphonic Acid Inhibitors of 
Autotaxin with Anti-Invasive and Anti-Metastatic Actions* 
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The ATX-LPA-LPA receptor axis is a promising therapeutic target for the management 
of cancer metastasis and therapeutic resistance. ATX shows feedback inhibition by its 
hydrolysis products LPA, CPA, and sphingosine-1-phosphate (S1P).18,19 Thus, many 
initially identified ATX inhibitors are lipid-like substrate or product analogs.9,165-171 The 
characteristics of this type of compounds limit their utility as potential lead compounds 
for drug development. Non-lipid ATX inhibitors have also been identified but most of 
these compounds lack sufficient potency and characterization in tumor models.1,167,172-176 
Recently, Ferry and colleagues described a non-lipid ATX inhibitor 
4-tetradecanoylaminobenzyl phosphonic acid (S32826, Figure 3.1) that possessed 
nanomolar activity in vitro.177 Unfortunately, S32826 failed to show activity in cellular 
and in vivo systems. We hypothesized that hydrolysis of the amide bond present in 
S32826 could be the reason for its instability and thus lack of activity in cellular systems. 
 
To overcome the presumed lack of stability of S32826, we designed analogs that were 
expected to be more stable than the parent compound. We have generated a panel of 
analogs that inhibit ATX with potencies comparable to that of S32826. These stabilized 
analogs inhibit ATX via a mixed-mode mechanism in vitro without any effect on the 
related lysophospholipid phosphodiesterases, NPP6 and NPP7 or on LPA receptors 
(LPAR). Two of these compounds, 30 and 38b inhibited ATX-dependent invasion of rat 
MM1 hepatoma cells of mesothelial cell and human umbilical cord vascular 
endothelialcell (HUVEC) monolayers in vitro. In addition, 30and 38b showed a profound 
reduction in lung foci in vivo using the B16-F10 syngeneic melanoma metastasis model 
in C57BL/6 mice. Based on these results compounds 30 and 38b represent promising 
leads for further synthetic improvement and also provide proof of principle that ATX 
inhibitors offer therapeutic utility in the control of cancer metastasis in vivo. 
 
Chemical Synthesis 
 
The synthesis 4-(hexadecane-1-sulfonylamino)benzyl phosphonic acid (12) is depicted in 
Scheme 3.1. Commercially available 1-hexadecanesulfonyl chloride (10) was added to a 
mixture of 4-aminobenzylphosphonic acid diethyl ester (9) and 
N,N-diisopropylethylamine in THF under reflux conditions to give compound 11, which 
was deprotected with bromotrimethylsilane (TMSBr) followed by addition of MeOH 
under stirring for 30 min to afford compound 12. The synthesis of compound 18 started 
with alkylation of 4-hydroxymethylphenol (13) (Scheme 3.2) using 1-bromotetradecane 
(14) in the presence of K2CO3 and 18-crown-6 to get compound 15 followed by treatment 
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Figure 3.1. ATX Inhibitor S32826. 
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Scheme 3.1. Synthesis of Compound 12. 
Reagents and conditions: (a) N,N-diisopropylethylamine,THF, reflux, 24h; (b) TMSBr, 
CH3CN, Reflux, 1h; (c) MeOH, 30min, rt. 
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Scheme 3.2. Synthesis of Compound 18. 
Reagents and conditions: (a) K2CO3, 18-crown-6, acetone, reflux, 16h; (b) PBr3, ether, rt, 
30min; (c) P(OMe)3, reflux,18h; (d) TMSBr, CH3CN, Reflux,1h; (e) MeOH, 30min, rt. 
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with PBr3 to obtain 16 in 98% yield. The Michealis–Arubuzov reaction178 on compound 
16 in trimethyl phosphate provided compound 17, which was then deprotected using 
TMSBr in anhydrous acetonitrile to yield 18. 
 
Scheme 3.3 demonstrates the synthesis of (E)-4-(pentadec-1-enyl)benzylphosphonic acid 
(26) and 4-pentadecylbenzylphosphonic acid (30). (E)-Methyl 4-(pentadec-1-enyl) 
benzoate (21) was synthesized by the Heck coupling of 19 and 20 using Palladium (II) 
acetate, and triethyl amine in anhydrous DMF. Compound 21 was reduced using LAH in 
THF at 0°C to room temperature to produce 22 and also saturated under catalytic 
hydrogenation conditions to generate compound 23. Bromination of Compound 22 with 
PBr3 in ether gave 24 which was then subjected to the Michealis–Arubuzov reaction178 
using trimethyl phosphite to get 25. Compound 25 was treated with TMSBr in 
acetonitrile followed by addition of MeOH to furnish 26. Compound 30 was synthesized 
utilizing the same approach starting from compound 23. The synthesis of 6-substituted 
naphthalen-2-yl-methyl phosphonic acid analogs (38a-b & 42a-b) was synthesized using 
the same procedure described for the synthesis of compounds 34 and 30 (Scheme 3.4). 
We then focused our medicinal chemistry efforts on phosphomimetic functional groups, 
the phosphomimetics include compounds 45, 49, 50, and 51 (Scheme 3.5). We started 
with the conversion of compound 27 into an aldehyde derivative 43 using pyridinium 
dichromate (PDC) in CH2Cl2. The resulting aldehyde 43 was then converted to the 
α-hydroxy phosphonate derivative 36 using the Pudovik reaction.169, 179 Compound 44 
was deprotected using TMSBr to produce target compound 45. Compound 44 was treated 
with DAST in ether, SOCl2/CH2Cl2 and PBr3/ether to obtain the desired compounds 46, 
47, and 48, respectively. Finally, the compounds 46, 47, and 48 were treated with TMSBr 
followed by addition of MeOH to afford compounds 49, 50, and 51 in good yields. 
 
The synthesis of target compounds 53 and 55 is outlined in Scheme 3.6. Compound 27 
was treated with a mixture of 1H-tetrazole and bis(2-cyanoethyl) 
N,N-diisopropylphosphoramidite in anhydrous CH2Cl2 followed by the addition of 
hydrogen peroxide to give the bis-cyanoethylprotected fatty alcohol phosphate 52. 
Removal of the cyano ethyl groups with treatment of methanolic KOH followed by  
acidification furnished the phosphate 53. Similarly 27 was treated with a mixture of 
1H-tetrazole and bis(2-cyanoethyl) N,N-diisopropylphosphoramidite in anhydrous 
CH2Cl2 followed by reflux in the presence of elemental sulfur to give bis-cyanoethyl 
protected fatty alcohol thiophosphate 38, which, in turn, was treated with methanolic 
KOH followed by acidification to yield the thiophosphate 55. 
 
 
Biological Results 
 
 
Effect of 4-Substituted Benzyl Phosphonic Acid and 6-Substituted Naphthalene-2yl-
Methyl Phosphonic Acid Derivatives on Autotaxin and LPAR 
 
The first level of testing was done using 10 µM concentrations of the compounds added 
to 2 nM recombinant human ATX and the FRET substrate FS-3. After a 2h incubation 
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Scheme 3.3. Synthesis of Compounds 23 and 30. 
Reagents and conditions: (a) Pd(OAc)2, Et3N, DMF, reflux, 16h; (b) LAH, THF, 0°C-rt, 
4h; (c) H2/Pd/C, MeOH; (d) PBr3, ether, rt, 30min; (e) P(OMe)3, reflux, 18h; (f) TMSBr, 
CH3CN, Reflux,1h; (g) MeOH, 30min, rt. 
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Scheme 3.4. Synthesis of Compounds 38a-b and 42a-b. 
Reagents and conditions: (a) Pd(OAc)2,Et3N, DMF, reflux, 16h; (b) LAH, THF, 0°C-rt, 
4h; (c) H2/Pd/C, MeOH; (d) PBr3, ether, rt, 30min; (e) P(OMe)3, reflux, 18h; (f) TMSBr, 
CH3CN, Reflux,1h; (g) MeOH, 30min, rt. 
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Scheme 3.5. Synthesis of Compounds 45, 49, 50 and 51. 
Reagents and conditions: (a) PDC, DCM, rt, 16h; (b) HP(OCH3)2, Et3N, 0°C-rt, 4h; (c) 
TMSBr, CH3CN, Reflux,1h; (d) MeOH, 30min, rt; (e) DAST, ether, 0°C-rt, 1h; (f) 
SOCl2, DCM, reflux, 1h; (g) PBr3, ether, rt, 30min. 
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Scheme 3.6. Synthesis of Compounds 53 and 55. 
Reagents and conditions: (a)(i) bis(2-cyanoethyl)-N,N-diisopropylphosphoramidite, 
1H-tetrazole, CH2Cl2, rt; (ii) 50% H2O2; (b)(i) bis(2-cyanoethyl)-
N,N-diisopropylphosphoramidite,1H-tetrazole, CH2Cl2, rt; (ii) sulfur, reflux, 2h;  
(c)(i) KOH, MeOH; (ii) dil HCl. 
 
 
the amount of FS-3 hydrolyzed was measured and the residual ATX activity was 
expressed as a percent of the vehicle-treated sample less the autolysis of FS-3 in the 
absence of ATX. In this assay, S32826 reduced the amount of FS-3 hydrolyzed by 97% 
(Table 3.1 and Table 3.2). Among the 4-substituted benzyl phosphonic acid analogs 
compound 30 showed 95% inhibition of FS-3 hydrolysis (Table 3.1), whereas 
compound38b from the 6-substituted naphthalene-2yl-methyl phosphonic acid series 
reduced FS-3 hydrolysis by 83% (Table 3.2). Dose-response curves were generated with 
compounds S32836, 30 and 38b and compared to the feedback inhibition of the ATX 
product LPA (Figure 3.2). Each of these three compounds dose-dependently and 
completely inhibited ATX. The ATX inhibition assays were carried out in Dr.Tigyi’s 
laboratory. 
 
Subsequently, we generated analogs of compounds 22 and 38b and examined their 
inhibition of ATX. The modifications were either in the aliphatic chain, the linker of the 
phosphate moiety, or on the phosphate moiety itself (Table 3.1 and Table 3.2). The most 
effective analogs based on the single 10-µM dose inhibition assay were extensively 
characterized to determine IC50, Ki, and Ki’ values against ATX-mediated hydrolysis of 
FS-3. Replacement of the amide with a sulfonamide (12) reduced potency. Introduction 
of an ether (18) or alkene (26) connecting the hydrocarbon chain to the benzyl ring 
decreased the potency compared to the simple aliphatic chain. Linkage of the phosphate 
moiety in compound 53 through a methyl phosphonate reduced efficacy. 
 
However, converting the phosphate to a thiophosphate (55) in this scaffold increased 
efficacy at 10 µM 5.6-fold. α-Halogenation of the linker methyl group generally 
decreased potency of compounds 49, 50, and 51 relative to compound 30. Insertion of a 
α-hydroxyl group into the linker methylene increased the potency of this analog but it did 
not surpass that of compound 30. 
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Table 3.1. Characterization of Benzyl Phosphonic Acids at ATX, NPP6 and NPP7.  
 
 
 
Compound X Y R 
ATX 
Activity, 
% Control 
(10µM) 
ATX 
IC50 
(µM) 
ATX 
Mechanism 
of 
Inhibition 
ATX 
Ki(µM) 
ATX 
Ki’ (µM) 
NPP6 
Activity, 
% Control 
(10µM) 
NPP7 
Activity, 
% Control 
(10µM) 
S32826 O CH2 HN C13H27
O
 
2.6 ND ND N/A N/A 102.1 101.2 
12 O CH2 HN S C16H33
O
O
 
24.1 ND ND N/A N/A 102.0 93.5 
18 O CH2 O C13H27
 
30.4 ND ND N/A N/A 102.0 100.6 
26 O CH2 C13H27  18.8 ND ND N/A N/A 104.0 97.7 
30 O CH2 C13H27  5.2 0.17 Mixed 0.27 0.28 96.5 96.7 
45 O CHOH C13H27  9.2 0.73 Mixed 0.45 0.70 99.6 101.0 
49 O CHF C13H27  42.3 17.9 Mixed 4.97 5.54 101.1 102.6 
50 O CHCl C13H27  117.9 ND ND N/A N/A 100.6 99.9 
51 O CHBr C13H27  60.1 10.1 Mixed 6.10 2.97 99.3 99.5 
53 O O-CH2 C13H27  85.2 ND ND N/A N/A 100.9 98.8 
55 S O-CH2 C13H27  15.2 1.54 Mixed 4.45 4.43 98.8 92.9 
 
ND – not determined, NA – not applicable since the mechanism of inhibition was not determined. 
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Table 3.2. Characterization of Naphthylphosphonic Acids at ATX, NPP6 and NPP7. 
 
 
 
Compound X Y R 
ATX 
Activity, 
% Control 
(10µM) 
ATX 
IC50 
(µM) 
ATX 
Mechanism 
of Inhibition 
ATX 
Ki(µM) 
ATX 
Ki’ (µM) 
NPP6 
Activity, 
% Control 
(10µM) 
NPP7 
Activity, 
% Control 
(10µM) 
38a O CH2 C10H21  61.3 ND ND N/A N/A 103.1 100.0 
38b O CH2 C11H23  17.3 1.40 MIXED 1.50 1.01 104.1 96.5 
42a O CH2 C10H21  19.9 ND ND N/A N/A 101.0 98.8 
42b O CH2 C11H23  50.8 ND ND N/A N/A 100.0 94.7 
 
ND – not determined, NA – not applicable since the mechanism of inhibition was not determined. 
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Figure 3.2. Inhibition of ATX-Mediated Hydrolysis of FS3 by LPA, S32826, 
Compound 30, or 38b. 
ATX (2nM) and 1 µM FS3 were incubated in the presence of increasing concentrations 
of the inhibitors for 2h and the fluorescent product was measured and expressed as 
percent of FS3 hydrolysis by ATX in the presence of vehicle less the autolysis of FS3 
(n = 3 ± SD). 
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Modification of the side chain at position 6 of the naphthalene-2yl-methyl phosphonic 
acid scaffold showed that the 10-carbon side chain was more effective than the 11 carbon 
chain and that incorporation of an alkene had differential effects depending on the chain 
length (decreased efficacy of compound 38a relative to 42a, but increased efficacy of 38b 
over 42b). Analysis of the seven analogs showed that compound 30 in the benzyl 
phosphonic acid series and compound 38b in the naphthalene-methyl phosphonic acids 
were the most potent analogs with respect to ATX inhibition. 
 
In order to determine the mechanism of ATX inhibition, Ki (affinity of the compound for 
free enzyme) and Ki' (affinity of the compound for the enzyme substrate complex) were 
determined using simultaneous nonlinear fits of the Michaelis-Menten equations for 
competitive, uncompetitive, mixed-mode, and non-competitive inhibition as we have 
previously described.172,175,180 These experiments uniformly showed that these 
compounds displayed similar Ki and Ki’ values which is consistent with a mixedwork-
mode type mechanism of inhibition.NPP6 and NPP7 are the only NPP isoforms beyond 
ATX that are known to utilize lysophospholipid phosphodiesters as substrates. Thus, 
specificity was addressed by determining the activity of NPP6 and NPP7 in the presence 
and absence of these analogs. None of the analogs tested blocked the activity of NPP6 or  
NPP7 by greater than 10% at a single 10 µM dose (Table 3.1 and Table 3.2).The 
mechanism of inhibition of the comounds and their effect on NPP6 and NPP7 were 
carried out by Dr. Bakers group at the University of Memphis. 
 
Some inhibitors of ATX, including LPA phosphonates165 and LPA 
bromophosphonates,170 have been shown to inhibit ATX and block LPA receptor 
subtypes. LPA bromophosphonate (LPA-BP) was also shown to inhibit cancer metastasis 
and reduced tumor size in mice.170 For this reason, we examined whether the two leads 
30 and 38b affected the activation of multiple LPA GPCR targets using cell lines 
overexpressing individual LPA GPCR coupled to Ca2 + mobilization as we have 
previously described.170 Analyses were done using 10 µM concentrations of the test 
compounds alone or in combination with an EC50 concentration of LPA for the given 
receptor subtype to determine agonist and antagonist activity, respectively (Table 3.2). 
 
Some of the compounds that showed > 10% attenuation of the LPA response or 
activation > 10% of LPA at a given receptor subtype at 10 µM were subjected to dose-
response/inhibition experiments (Table 3.3). Unexpectedly, compounds 53 and 55 were 
weak but full agonists at LPA5 with EC50 values of 7.9 µM and 2.9 µM, respectively. 
Compound 55 was also a partial agonist at LPA3 (Emax10µM ~ 44% of the maximal LPA 
response). Compound 53 caused a 50% reduction in the LPA2 response when applied at 
10 µM. Compound 41b elicited a 33% activation of LPA3 and a17% activation at LPA5 
when applied at 10 µM. Likewise, compound 30 (10 µM) was a weak partial agonist at 
LPA2 (Emax10µM ~ 20%) whereas, analogs 45 and 49 inhibited this receptor subtype by 
28% and 26%, respectively. Based on these findings we conclude that these analogs were 
poor ligands of the LPA GPCR tested with the exception of compounds 53 and 55, which 
were full albeit weak agonists of LPA5. At the present time, very few LPA5 selective 
compounds have been described in the literature52 hence the identification of these two  
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Table 3.3. Characterization at LPA Receptors. 
 
 
Compound 
RH7777 
Vector 
Emax10µM 
(% of ATP) 
 
LPA1 
(Emax10µM) 
 
LPA2 
(Imax10µM) 
 
LPA3 
(Emax10µM) 
 
CHO Vector 
Emax10µM  
(% of ATP) 
 
LPA4 
 
 
B103 Vector 
Emax10µM  
(% of ATP) 
 
LPA5 
(Emax10µM) (Imax10µM) 
30 > 1 NE 23 22 > 1 NE > 3 NE NE 
38b > 6 NE NE 33 > 1 NE > 3 17 NE 
45 > 1 NE 28 NE NE NE NE NE 51 
49 > 3 NE 26 17 > 5 NE > 1 NE NE 
51 > 5 NE NE NE > 5 NE > 2 NE NE 
50 > 15 ND ND ND > 74 ND > 32 ND ND 
53 > 6 NE 50 13 > 14 NE > 2 100 
(EC50 =  
7.9 µm) 
NE 
55 > 7 10 NE 44 > 14 NE > 3 100 
(EC50 =  
2.9 µm) 
NE 
 
NE – no effect, ND – not definable due to effect on vector transfected cells, EMAX 10µM – maximal response at 10 µM relative to the 
maximal response to either ATP in vector transfected cells or to LPA in LPA receptor expressing cells.  
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hits might serve as a starting point for a more comprehensive characterization of the 
structure-activity relationship of this receptor subtype. 
 
 
ATX Inhibitors Block Hepatocarcinoma Invasion of Mesothelial and HUVEC 
Monolayers 
 
Cancer metastasis is a complex process that cannot be accurately modeled in vitro. 
Models that utilize cellular monolayers for the invasion of carcinoma cell come the 
closest to the situation in vivo.181-184 Here we used two different cell monolayers, mouse 
mesothelium and human vascular endothelium to examine the role of ATX in the 
invasion of MM1 hepatocarcinoma cells. The mesothelial monolayer is an accepted 
model for invasion of body cavities lined by serous cells whereas, the HUVEC 
monolayer is considered to be an in vitro model of hematogenous invasion of carcinomas.  
 
The mesothelial and HUVEC cells of the monolayer and the invading MM1 cells express 
different levels of ATX (Figure 3.3A-C). Quantitative real-time PCR performed with 
mRNA isolated from MM1, mesothelium and HUVEC cells showed that the primary 
source of ATX is the MM1 cell as the other two cell types showed very low expression. 
MM1 cells showed robust expression of transcripts encoding the P2Y family of LPA 
receptors and LPA2 in the EDG receptor subfamily. In mesothelial cells LPA2 is the 
predominant receptor whereas, in HUVECs it is the LPA5 receptor. 
 
Addition of LPC to the co-culture increases invasion in a dose-dependent manner (Figure 
3.3D). We hypothesized that inhibition of ATX by our two lead compounds should 
attenuate LPA production in situ and reduce invasion of MM1 carcinoma cells through 
the mesothelial and HUVEC monolayers. Compounds 30 and 38b were applied with or 
without LPC to the co-cultures and the number of invading cells was quantified after 24 h 
of the co-culture (Figure 3.3E). Both compounds inhibited MM1 cell invasion reaching a 
complete inhibition of LPA and likely ATX-dependent invasion above 3 µM. The two 
compounds were also tested for their ability to inhibit MM1 cell invasion of HUVEC 
monolayers (Figure 3.3F). Similarly to that seen for the invasion of murine mesothelial 
monolayers, compounds 30 and 38b dose-dependently inhibited the LPC-dependent 
invasion of the HUVEC monolayer whereas, the compounds alone did not reduce the 
basal rate of invasion. These results provide evidence that the inhibition of ATX in situ 
can fully inhibit LPC-dependent invasion of carcinoma cells suggesting the potential 
applicability of our compounds in animal models of carcinoma metastasis. This study 
was performed in Dr. Tigyis Laboratory. 
 
 
ATX Inhibitors Reduce B16 Melanoma Metastasis In Vivo 
 
Inhibitors of ATX have been shown to reduce tumor metastasis in different animal 
models.9,170 Here we applied the syngeneic B16-F10 mouse melanoma model of 
hematogenous lung metastasis in C57BL/6 mice that we previously showed responds to 
inhibitors of ATX.9 C57BL/6 mice were inoculated with B16-F10 melanoma cells via the  
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Figure 3.3. Profiling of LPA Receptor and ATX Transcripts. 
MM1cells (A), mouse mesothelial (B) and HUVEC cells (C) using quantitative real-time 
PCR. (D) LPC dose-dependently increases the invasion of mesothelial monolayers by 
MM1 cells. (E) Compounds 30 and 38b dose dependently inhibit the invasion of 
mesothelial monolayers induced by LPC (1.5 µM) that is reduced to the level of control 
at and above 3 µM concentration. (F) Compounds 30 and 38b block LPC-induced but do 
not alter the basal rate of invasion of HUVEC monolayers by MM1 cells. * Denotes  
p < 0.05 based on Student’s t-test. 
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tail vein. Beginning 30 min later the mice were treated with either 0.5 mg/kg/injection of 
the two lead compounds or vehicle (PBS with 1% DMSO) via the intraperitoneal route 
for an additional 10 days. As a positive control, we also applied LPA-BP that we showed 
previously to inhibit the metastasis of breast and colon cancers in xenograft models.170,185 
On day 21 the animals were sacrificed and the lungs were isolated and metastatic nodules 
in the lungs were quantified (Figure 3.4). In this metastasis model, compounds 30 and 
38b In the present study we provide evidence for the potential therapeutic utility of ATX 
inhibitors derived from the benzyl phosphonic acid scaffold. The in vivo testing was 
carried out at the MD Anderson Cancer Center by Dr.Mills Laboratory. We have 
modified and expanded this scaffold to 6-substituted naphthalene-methyl phosphonic acid 
derivatives that were also effective inhibitors of ATX. Our limited structure-activity 
analysis showed that some of these compounds are high potency inhibitors of ATX 
without significant effects on LPA GPCR in the nanomolar and low micromolar range. 
Unlike the parent compound S32826 that lacked activity in cellular assays,177 these novel 
analogs showed strong inhibition of ATX-mediated tumor cell invasion of mesothelial 
and endothelial cell monolayers and were as effective in vivo as the previously reported 
dual action ATX inhibitor and LPA GPCR antagonist LPA-BP.9,170,185 
 
There is increasing interest in developing inhibitors of ATX to control the tumor 
promoting and pro-inflammatory roles of LPA.166,167,170,172-175,186 Carba cyclic-
phosphatidic acid was the first ATX inhibitor scaffold explored to control carcinoma 
invasion and metastasis in vivo.9 Carba cyclic-phosphatidic acid inhibited ATX without 
activating LPA1-4. However, these compounds activate LPA5 that complicates their 
utility.52 Subsequently, the sn-1 or sn-2 hydroxy groups of LPA have been replaced by 
fluorine, difluoromethyl, difluoroethyl, O-methyl or O-hydroxyethoxy groups to give 
non-migrating LPA analogues that resist acyltransferases187 and some of these 
compounds, including LPA-BP, have been found to possess dual action by inhibiting 
ATX and LPA GPCR.170 LPA-BP inhibited breast cancer metastasis and tumor growth in 
vivo.170 Several new ATX inhibitor scaffolds have been reported recently,166,167,172-175,186 
however, these compounds have not been evaluated at other members of the NPP family 
and were not explored for their ability to control invasion and/or metastasis. Our study 
for the first time provides proof of the principle that non-lipid ATX inhibitors are capable  
of controlling cancer metastasis in vivo and also validate the monolayer invasion assay as 
a valuable cell-based screening for antimetastatic compounds. 
 
The preclinical screening template consisting of assaying the activity of analogs against 
ATX, followed by related NPP isoforms, LPA GPCR, monolayer invasion assays, 
followed by the syngeneic animal metastasis model offers a comprehensive stepwise 
protocol for the identification of ATX inhibitors with utility to control tumor progression. 
Given the relatively short half-life of ATX188 and the high rate of LPA turnover in vivo167 
we foresee the need of compounds with long plasma half-life and broad tissue 
distribution to control the constitutive production of ATX and the generation of LPA. The 
present data derived from cellular and in vivo experiments suggest that further 
modification of the benzyl and naphthyl phosphonic acid scaffolds might yield suitable 
derivatives for the control of carcinoma metastasis. Pharmacokinetic profiling will be a 
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Figure 3.4. Effect of Compound 30, 38b, and LPA-BP on the Lung Metastasis of 
B16-F10 Melanoma. 
(A) Representative lungs taken from the treatment groups. (B) Lung nodule counts in the 
treatment groups. * Denotes p < 0.05 relative to vehicle. 
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crucially important step in further evaluation and preclinical development of ATX 
inhibitors and such experiments are underway in our laboratories. 
 
 
Experimental Section 
 
 
Chemistry 
 
All starting materials, reagents and solvents were obtained from commercial suppliers 
and were used without further purification. Reactions were performed under an inert 
atmosphere of argon, unless otherwise specified. Routine thin-layer chromatography 
(TLC) was performed on silica gel plates (Analtech, Inc., 250 microns). Flash 
chromatography was conducted on silica gel (Merck, grade 60, 230-400 mesh). 1H NMR 
spectra were recorded on a Bruker ARX 300 spectrometer (300 MHz) or Varian 
spectrometer (500MHz) using DMSO-d6 and CDCl3 as solvents, and spectral data were 
consistent with assigned structures. Chemical shift values were reported as parts per 
million (δ), coupling constants (J) are given in Hz, and splitting patterns are designated as 
follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet. Mass spectra were 
collected on a Brucker ESQUIRE electrospray/ion (ESI) trap instrument in the positive 
and negative modes. High-resolution mass (HRMS) measurements were obtained using a 
Micromass Q-TOF2 mass spectrometer. Elemental analyses (C, H, N) was performed by 
Atlantic Microlab, Inc. (Norcross, GA), and results were within ± 0.4% of the theoretical 
values for the formula given. 
 
Diethyl 4-(hexadecylsulfonamido)benzylphosphonate (11):1-hexadecanesulfonyl 
chloride 10 (0.66g, 2.05mmol) was added to a mixture of 9 (0.5g, 2.05 mmol) and 
N,N-diisopropylethylamine (0.04g, 2.05mmol) in THF and refluxed for 24h to obtain 
compound 11. The reaction mixture was concentrated under high vacuum and purified by 
flash column chromatography (CHCl3/MeOH 3:1) to give 0.524 g of pure 11 (0.524g, 
48%) as a yellow solid. 1H NMR (300 MHz, [D6] DMSO): δ = 9.71 (s, 1H ), 7.10-7.25 
(overlapping signals, 4H)  3.897-3.948 (p, 4H, J = 7.8Hz), 3.11-3.18 (d, 2H, J = 21 Hz) 
3.07-2.95 (t, 2H, J = 9 Hz) 1.7-1.56 (p, 2H) 1.231 (s, 26H) 1.171-1.123 (t, 6H, J = 7.2) 
0.9-0.8 (t, 3H); MS (ESI) m/z 530.2 [M-H]-. 
 
General procedure for synthesis of Phosphonic acid analogs (Compounds 12, 18, 26, 30, 
38a, 38b, 42a, 42b, 45, 49, 50 and 51) (GP 1): To a suspension of phosphonate derivative 
(1 equiv) in anhydrous acetonitrile, TMSBr (2.5 equiv) was added and the reaction 
mixture was refluxed for 1 h. The acetonitrile was then evaporated under reduced 
pressure and MeOH was added to the residue and stirred for 30 minutes at RT. The 
desired product was obtained in good yield after filtration of MeOH solution as a white 
solid. 
 
General procedure for synthesis of compounds 16, 24, 28, 36a, 36b, 40a, 40b and 48 (GP 
2): PBr3 (0.3 equiv) was added slowly under stirring to a solution of alcohol derivative 
(1 equiv) in anhydrous DCM at 0°C. The reaction mixture was stirred at room 
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temperature for 1h and the formation of the product was monitored by TLC. Water was 
added at 0°C to quench the reaction, extracted from the DCM and dried over MgSO4. The 
product was carried on to the next step without further purification. 
 
General procedure for synthesis of compounds 17, 25, 29, 37a, 37b, 41a and 41b (GP 3): 
Trimethylphosphite (9 equiv) was added to dry bromide derivative (1 equiv)at room 
temperature and the mixture was refluxed for 18h. The trimethylphosphite was 
evaporated under high vacuum overnight and the crude residue was purified by column 
chromatography (CHCl3/MeOH 3:1) to give pure compound in quantitative yield. 
 
General procedure for synthesis of compounds 29, 33a and 33b (GP 4): To a mixture of 
aryl bromide derivative (1 equiv), Palladium (II) acetate (5 mol%), and triethyl amine 
(1 equiv) in anhydrous DMF was added substituted alkene (1 equiv) successively. The 
reaction mixture was refluxed for 16 h, filtered on bed of celite and extracted with 
ethylacetate and water. The compound was purified by flash column chromatography 
using ethyl acetate and hexane (1:2) mixture.  
 
General procedure for synthesis of Compound 22, 27, 34a, 26b, 39a and 31b (GP 5): 
Anhydrous THF was added to LAH (3 equiv) and stirred for 5 minutes. To this, a 
solution of corresponding methyl ester (1 equiv) in THF was added and the mixture was 
stirred at room temperature for 4h. The reaction mixture was cooled to 0°C and saturated 
sodium sulfate was added drop-wise to the mixture. The product was then extracted with 
ethyl acetate and the crude product was purified using flash column chromatography 
which was eluted with ethyl acetate and hexane mixture (1:1). 
 
General procedure for the synthesis of compounds23, 27a and 27b (GP 6): To a solution 
of the corresponding alkene of the methyl ester derivative (1 equiv) in MeOH was added 
catalytic amounts of Pd(OH)2/C and the mixture was stirred at room temperature for 2h 
using catalytic amount of hydrogen gas. The completion of reaction was monitored by 
TLC and the reaction mixture was filtered on a bed of celite. The filtrate was evaporated 
and purified by column chromatography (Chloroform:methanol 30:1). 
 
4-(Hexadecane-1-sulfonylamino)benzyl phosphonic acid (4): According to general 
procedure GP 1 compound 4 was obtained as a solid (0.093gm, 53%). 1H NMR (500 
MHz, [D6] DMSO): δ = 9.66 (d, 1H, J = 20 Hz) 7.18-7.08 (m, 4H); 3.04-2.97 (m, 2H); 
2.91 (d, 2H, J = 20 Hz); 1.64-1.61(m, 2H) 1.3-1.2 (s, 26H) 0.86-0.83 (t, 3H, J = 6 Hz); 
MS (ESI) m/z 474.0 [M-H]-; Anal Calcd. For C23H42NO5PS : C, 58.08; H, 8.90; N, 2.94. 
Found: C, 58.31; H, 9.01; N, 2.92. 
 
4-(Tetradecyloxy)phenyl methanol (15): Anhydrous K2CO3 (0.556g, 4.02 mmol) and 
18-crown-6 (0.02 g, 0.076 mmol) were added to a solution of 13 (0.5g, 4.03mmol) in 
acetone (20 mL) and the mixture was refluxed for 16h. The acetone was evaporated and 
the residue was partitioned between water and CH2Cl2. Pure compound 15 (1.11gm, 
86%) was obtained after flash column chromatography (CHCl3/MeOH 3:1). 1H NMR 
(300 MHz, CDCl3) δ = 7.27 (d, 2H); 6.9 (d, 2H); 4.6 (d, 2H); 3.9(t, 2H); 1.8 (p, 2H); 1.3 
(s, 20H); 0.8 (t, 3H); MS (ESI) m/z 319.0 [M-H]-. 
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Dimethyl-4-(tetradecyloxy)benzylphosphonate (25): Compound 25 was obtained 
according to GP 3. 1H NMR (300 MHz, CDCl3) δ = 7.2 (d, 2H); 6.9 (d, 2H); 3.93 (t, 2H); 
3.68 (d, 6H, J = 10.8 Hz); 3.1 (d,2H, J = 21 Hz); 1.8 (m, 2H); 1.3 (s, 20H); 0.88 (t, 3H); 
MS (ESI) m/z 435.4 [M + Na] + . 
 
4-(Tetradecyloxy)benzylphosphonic acid (18): The acid 18 was prepared similar to the 
GP 1and it was obtained as a white solid (0.137gm, 54%). 1H NMR (500 MHz, [D6] 
DMSO): δ = 7.135 (d, 2H); 6.82 (d, 2H);  3.91 (t, 2H); 2.8 (d,2H, J = 21 Hz); 1.69 (m, 
2H); 1.386 (m, 2H); 1.24 (s, 22H); 0.85 (t, 3H); MS (ESI) m/z 383.0 [M-H]-; Anal calcd. 
For C21H37NO4P : C, 65.60; H, 9.70. Found C, 65.83; H, 9.81. 
 
(E)-Methyl-4-(pentadec-1-enyl)benzoate (21): Compound 21 was prepared according to 
GP 4. 1H NMR (300 MHz, CDCl3) δ = 7.92-7.5 overlapping protons (m, 4H); 6.4 
(m,1H); 5.4 (m,1H); 3.92 (s, 3H); 2.1-1.9 (m, 2H); 1.7-1.5 (m, 2H); 1.3 (s, 20H); 0.865 
(t, 3H). MS (ESI) m/z 367.3 [M + Na] + . 
 
(E)-4-(Pentadec-1-enyl)phenyl methanol (22): Compound 22 was synthesized according 
to GP 5. 1H NMR (300 MHz, CDCl3) δ = 7.6-7.1 overlapping protons (m, 4H); 6.4-6.2 
(m,1H); 5.5-5.3 (m,1H); 4.67 (s, 3H); 2.1-1.9 (m, 2H); 1.7-1.5 (m, 2H); 1.27 (s, 20H); 
0.895 (t, 3H). MS (ESI) m/z 339.5 [M + Na] + . 
 
Methyl-4-pentadecylbenzoate (23): The compound was verified with Mass spectrometry 
and carried on to the next step. MS (ESI) m/z 347.3 ([M + H]); m/z 369.3 [M + Na] + . 
 
(E)-Dimethyl-4-(pentadec-1-enyl)benzylphosphonate (25): Compound 25 was obtained 
according to GP 3. 1H NMR (300 MHz, CDCl3) δ = 7.3-7.1 overlapping protons (m, 4H); 
6.4-6.2 (m,1H); 5.5-5.3 (m,1H); 3.65 (d, 6H); 3.2 (d, 2H); 2.1-1.9 (m, 2H); 1.7-1.57 
(m, 2H); 1.27-1.2 (s, 20H); 0.895 (t, 3H). MS (ESI) m/z 431.3 [M + Na] + . 
 
(E)-4-(Pentadec-1-enyl)benzylphosphonic acid (18): Compound 18 was prepared similar 
to GP 1and was obtained as a white powder (0.047gm, 51%). 1H NMR (500 MHz, [D6] 
DMSO): δ = 7.281-7.07 overlapping protons (m, 4H); 6.36-6.22 (m,1H); 5.36 (m,1H); 
2.93(d, 2H); 2.15 (d, 2H); 1.95 (m, 2H); 1.57 (m,2H); 1.237(s, 20H); 0.853 (t, 3H). MS 
(ESI) m/z 379.0 [M-H]-; HRMS (QTOF) for C22H37O3P, calcd: 379.2402; found: 
379.2412. 
 
(4-Pentadecylphenyl)methanol (27): Compound 27 was obtained according to GP 5, 
verified with Mass spectrometry and carried on to the next step. MS (ESI) m/z 341 
[M + Na] + . 
 
Dimethyl-4-pentadecylbenzylphosphonate (29): Compound 29 was synthesized similar to 
GP 3. 1H NMR (300 MHz, CDCl3) δ = 7.4-7.0 overlapping protons (m, 4H); 3.66-3.63 
(d,6H, J = 15 Hz); 3.2 (d, 2H); 2.6 (m, 2H); 1.6 (m, 2H); 1.2 (s, 24H); 0.895 (t, 3H). MS 
(ESI) m/z 433 [M + Na] + . 
 
 
 40 
4-Pentadecylbenzylphosphonic acid (30): Compound 30 was obtained according to GP 
1as a white powder (0.153gm, 53%). 1H NMR (500 MHz, [D6] DMSO): δ = 7.139-7.063 
overlapping protons (m, 4H); 2.91(d, 2H, J = 20 Hz); 1.52 (m, 2H); 1.26(m, 2H); 
1.15(s, 24H); 0.853 (t, 3H). MS (ESI) m/z 381.0 [M-H]-; Anal Calcd.for C22H39O3P; C, 
69.08; H, 10.28; Found C, 69.33; H, 10.52. 
 
(E)-methyl-6-(dodec-1-enyl)-2-naphthoate (25a): According to GP 4 compound 25a was 
prepared. 1H NMR (300 MHz, [D6] DMSO): δ = 8.582-7.771 overlapping protons (6H); 
6.65-6.52 (m, 1H); 5.7-5.2 (m,1H); 3.91-3.90 (s, 3H); 2.1-1.8 (m, 2H); 1.76-1.55(m, 2H); 
1.209(s, 14H); 0.856 (t, 3H). MS (ESI) m/z 375.3 [M + Na] + . 
 
(E)-Methyl-6-(tridec-1-enyl)-2-naphthoate(25b): Compound 25b was prepared similar to 
GP 4. 1H NMR (300 MHz, CDCl3) δ = 8.582-7.771 overlapping protons (6H); 6.65-6.52 
(m, 1H); 5.7-5.2 (m,1H); 3.91-3.90 (s, 3H); 2.1-1.8 (m, 2H); 1.76-1.55(m, 2H); 1.209 
(s, 14H); 0.856 (t, 3H).   MS (ESI) m/z 389.3 [M + Na] + . 
 
(E)-6-(Dodec-1-enyl) naphthalen-2-yl-methanol (34a): Compound 34a was obtained 
according to GP 5. 1H NMR (300 MHz, CDCl3) δ = 7.9-7.3 overlapping protons (6H); 
6.6-6.3 (m, 1H); 5.6-5.4 (m,1H); 4.814(s, 2H); 2.35-2.26 (m, 2H); 1.6-1.47(m, 2H); 
1.268(s, 14H); 0.9 (t, 3H). MS (ESI) m/z 347.3 [M + Na] + . 
 
(E)-6-Tridec-1-enyl-naphthalen-2-yl-methanol (34b): Compound 34b was prepared 
according to GP 5. 1H NMR (300 MHz, CDCl3) δ = 7.72-7.27 overlapping protons (6H); 
6.6-6.3 (m, 1H); 5.6-5.4 (m,1H); 4.75(s, 2H); 2.35-2.26 (m, 2H); 1.6-1.47(m, 2H); 
1.268(s, 18H); 0.893 (t, 3H).MS (ESI) m/z 361.3 [M + Na] + . 
 
6-Dodecylnaphthalene-2-carboxylic acid methyl ester (27a): Compound 27a was 
prepared according to GP 6 and confirmed by Mass spectrometry. MS (ESI) m/z 355 
[M + H] + . 
 
6-Tridecylnaphthalene-2-carboxylic acid methyl ester (27b): Compound 27a was 
prepared similar to GP 6 and confirmed by Mass spectrometry. MS (ESI) m/z 369.3 
[M + H] + . 
 
(E)-Dimethyl-6-dodec-1-enyl-naphthalen-2-yl-methylphosphonate (37a): Compound 37a 
was obtained according to GP 3. 1H NMR (300 MHz, CDCl3) δ = 7.9-7.3 overlapping 
protons (6H); 6.6-6.3 (m, 1H); 5.6-5.4 (m,1H); 3.778-3.741 (d, 6H, J = 21.6 Hz); 
3.34-3.267 (d, 2H, J = 21.9 Hz); 2.35-2.26 (m, 2H); 1.6-1.47(m, 2H); 1.268(s, 14H); 0.9 
(t, 3H). MS (ESI) m/z 439.3 [M + Na] + . 
 
(E)-Dimethyl-6-tridec-1-enyl-naphthalen-2-yl-methylphosphonate (37b): Compound 37b 
was obtained similar to GP 3. 1H NMR (300 MHz, CDCl3) δ = 7.9-7.3 overlapping 
protons (6H); 6.6-6.3 (m, 1H); 5.6-5.4 (m,1H); 3.778-3.741 (d, 6H, J = 21.6 Hz); 
3.34-3.267 (d, 2H, J = 21.9 Hz); 2.35-2.26 (m, 2H); 1.6-1.47(m, 2H); 1.268 (s, 16H); 0.9 
(t, 3H). MS (ESI) m/z 453.3 [M + Na] + . 
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(E)-6-Dodec-1-enyl-naphthalen-2-yl-methylphosphonic acid (30a): According to GP 1 
compound 30a was prepared and was obtained as a white powder (0.027gm, 52%). 1H 
NMR (500 MHz, [D6] DMSO): δ = 7.747-7.329 overlapping protons (6H); 6.556-
6.630(m, 2H); 3.182 (d, 2H, J = 21 Hz); 2.221 (m, 2H); 1.468(m, 2H); 1.255 (s, 14H); 
0.836 (t, 3H). MS (ESI) m/z 387.0 [M-H]-; Anal calcd for C23H33O3P: C, 71.11; H, 8.56; 
Found: C, 70.73; H, 9.11. 
 
(E)-6-Tridec-1-enyl-naphthalen-2-yl-methylphosphonic acid (38b): Compound 38b was 
prepared similar to GP 1and was obtained as a white powder (0.117gm, 54%). 1H NMR 
(500 MHz, [D6] DMSO): δ = 7.811-7.327 overlapping protons (6H); 6.553-6.433(m,1H); 
5.353 (m,1H); 3.123-3.080 (d, 2H, J = 21.5 Hz); 2.730 (t, 2H); 1.98 (m, 2H);1.64-1.48 
(m, 2H); 1.244 (s, 14H); 0.841 (t, 3H). MS (ESI) m/z 401.0 [M-H]-; HRMS Calcd for 
C24H34O3P,401.2246; found: 401.2249. 
 
6-Dodecylnaphthalen-2-yl-methanol (39a): Compound 39a was synthesized according to 
GP 5. 1H NMR (300 MHz, CDCl3) δ = 7.9-7.3 overlapping protons (6H); 4.805 (s, 2H); 
2.817-2.792 (m, 2H); 1.833 (m, 2H); 1.372 (s, 16H); 0.963 (t, 3H). MS (ESI) m/z 325.0 
[M-H]-; m/z 349.3 [M + Na] + . 
 
6-Tridecylnaphthalen-2-yl-methanol (39b): Compound 39b was prepared according to 
GP 5. 1H NMR (300 MHz, CDCl3) δ = 7.9-7.3 overlapping protons (6H); 4.798 (s, 2H); 
2.857-2.7 (m, 2H); 1.833-1.6 (m,2H); 1.372 (s, 18H); 0.963 (t, 3H). MS (ESI) m/z 363.6 
[M + Na] + . 
 
2-Bromomethyl-6-dodecylnaphthalene (40a): Compound 40a was obtained according to 
GP 2. 1H NMR (300 MHz, CDCl3) δ = 7.9-7.3 overlapping protons (6H); 4.696 (s, 2H); 
2.817-2.792 (m, 2H); 1.833 (m, 2H); 1.372(s, 18H); 0.968 (t, 3H). 
 
Dimethyl-6-dodecylnaphthalen-2-yl-methylphosphonate (41a): Compound 41a was 
prepared to according to GP 3. 1H NMR (300 MHz, CDCl3) δ = 7.9-7.3 overlapping 
protons (6H); 3.691-3.655 (d, 6H, J = 10.8 Hz); 3.359-3.287 (d, 2H, J = 21.6 Hz); 
2.817-2.792 (m, 2H); 1.833-1.6 (m, 2H); 1.302 (s, 18H); 0.893 (t, 3H). MS (ESI) m/z 
441.3 [M + Na] + . 
 
Dimethyl-6-tridecylnaphthalen-2-yl-methylphosphonate (41b): Compound 41b was 
prepared according to GP 3 and confirmed by Mass spectrometry MS(ESI) m/z 455.3 
[M + Na] + . 
 
6-Dodecylnaphthalen-2-yl-methylphosphonic acid (42a): Compound 42a was obtained 
according to GP 1 and was obtained as a white powder (0.023gm, 49%). 1H NMR (500 
MHz, [D6] DMSO): δ = 7.637-7.326 overlapping protons (6H); 3.13591-3.064 (d, 2H, 
J = 21.3 Hz); 2.927 (m, 2H); 1.641 (m, 2H);1.263 (s, 18H); 0.849 (t, 3H). MS (ESI) m/z 
389.0 [M-H]-. HRMS calcd for C23H34O3P, 389.2246, found: 389.2237. 
 
6-Tridecylnaphthalen-2-yl-methylphosphonic acid (42b): Compound 42b was obtained 
according to GP 1 and was obtained as a white powder (0.036gm, 51%). 1H NMR (500 
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MHz, [D6] DMSO): δ = 7.637-7.326 overlapping protons (6H); 3.13591-3.064 (d, 2H, 
J = 21.3 Hz); 2.927 (m, 2H); 1.641 (m, 2H);1.263 (s, 18H); 0.849 (t, 3H). MS (ESI) m/z 
403.0 [M-H]-. Anal calcd for C23H33O3P: C, 71.26; H, 9.22; Found: C, 70.82; H, 9.17. 
 
4-Pentadecylbenzaldehyde (43): Pyridinium dichromate (0.827gm, 2.20mmol) was added 
to a solution of 27 (1.00g, 3.139 mmol) in CH2Cl2 and stirred the mixture at RT for 16 h. 
The completion of reaction was checked by TLC. The reaction mixture was filtered over 
a bed of silica gel and filtrate was evaporated under reduced pressure to give compound 
43 (0.854g, 86%), which was used without any further purification for the next step. MS 
(ESI) m/z 339.3 [M + Na] + . 
 
Hydroxy-4-pentadecylphenylmethyl phosphonic acid dimethyl ester (44): 
Dimethylphosphite (0.547mL) and triethyl amine (0.357mL) were added to dry 
compound 43 (0.953 g, 3.011mmol) at 0°C. The reaction mixture was stirred at RT for 4 
h and the progress of the reaction was monitored by TLC. The crude mixture was purified 
on a silica gel column using CHCl3:MeOH (30:1) to get compound 44 in 72% yield 
(0.926gm). 1H NMR (500 MHz, CDCl3) δ = 7.456-7.149 overlapping protons (4H);6.040 
(d,1H); 5.03 (d,1H, J = 11.5);3.77 (d,6H,J = 15); 2.584 (t, 2H), 1.601(m,2H);1.358 (t,2H); 
1.34(s, 20H); 0.878 (t,3H). MS (ESI) m/z 449.3 [M + Na] + . 
 
Hydroxy-4-pentadecylphenylmethylphosphonic acid (45): Compound 45 was prepared 
according to GP 1.and was obtained as a offwhite powder (0.093gm, 52%); 1H NMR 
(500 MHz, [D6] DMSO): δ = 7.332-7.054 overlapping protons (4H); 6.061 (s,1H); 4.629 
(d,1H, J = 13.5 Hz); 2.584 (overlapping with DMSO, 2H), 1.534(m, 2H); 1.067(s, 22H); 
0.838 (t, 3H). MS (ESI) m/z 397.0[M-H]-. HRMS calcd for C22H38O4P [M-H] 397.2508; 
found 397.2517. 
 
Fluoro-4-pentadecylphenylmethyl phosphonic acid dimethyl ester (46):To a solution of 
compound 44 (0.122g, 0.286mmol) in ether, diethylaminosulfurtrifluoride (DAST) 
(0.046g, 0.286mmol) was added at 0°C and stirred the reaction mixture  at r.t for 1 h. The 
reaction was quenched by the addition of ice/water, extracted with ether and the crude 
residue was purified over column chromatography (0.076gm, 62%). 1H NMR (500 MHz, 
CDCl3) δ = 7.937 (d,2H); 7.227 (overlapping protons ,2H); 5.731 (dd, 1H, J = 44.5 Hz); 
3.747 (d, 6H);  2.610 (t, 2H); 1.602 (m,2H) 1.228 (s, 24H); 0.878 (t, 3H).MS (ESI) m/z 
451.1[M + Na] + . 
 
Chloro-4-pentadecylphenylmethyl phosphonic acid dimethyl ester (47): Thionyl chloride 
(0.047g, 0.397mmol) was added to a solution of compound 44 (0.113g, 0.264mmol) in 
anhydrous CH2Cl2 and refluxed the reaction mixture for 1 h. The solvent was evaporated 
under reduced pressure to afford compound 47. MS (ESI) m/z 445.1(M + ). 
 
Bromo-4-pentadecylphenylmethyl phosphonic acid dimethyl ester (48): Compound 48 
was obtained according to GP 2 and it was used for the next step without further 
purification. 
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Fluoro-4-pentadecylphenylmethyl phosphonic acid (49): Compound 49 was obtained 
according to GP 1 (0.04gm, 53%). 1H NMR (500 MHz, [D6] DMSO): δ = 7.308 (m, 
overlapping protons, 4H); 6.669 (s, 1H,); 2.610 (overlapping DMSO peak , 2H); 1.602 
(m, 2H) 1.228 (s, 24H); 0.878 (t, 3H).MS (ESI) m/z 399.0 [M-H]-. HRMS calcd for 
C22H37FO3P ([M-H]) 399.2464; found 399.2461. 
 
Chloro-4-pentadecylphenylmethyl phosphonic acid (50): Compound 50 (0.011gm, 47%) 
was prepared similar to GP 1 . 1H NMR (500 MHz, CDCl3) δ = 7.781 (m,overlapping 
protons, 4H); 5.050 (s, 1H,); 2.580 (m, 2H); 1.581 (m, 2H) 1.185 (s, 24H); 0.875 (t, 3H). 
MS (ESI) m/z 415.0(M + ). HRMS calcd for C22H37ClO3P ([M-H]) 415.2169; found: 
415.2166. 
 
Bromo-4-pentadecylphenylmethyl phosphonic acid 51: Compound 51 (0.019gm, 52%) 
was prepared according to GP 1. 1H NMR (500 MHz, [D6] DMSO): δ = 7.409 
(m,overlapping protons, 4H); 4.781 (s, 1H,); 2.580 (overlapping with DMSO, 2H); 1.515 
(m, 2H) 1.225 (s, 24H); 0.846 (t, 3H). MS (ESI) m/z 458.9([M + ]); m/z 460.9([M + 2]). 
HRMS calcd for C22H37BrO3P ([M-H]) 459.1664; found: 459.1664([M-H]); 
461.1660(M + 2). 
 
Bis(2-cyanoethyl) 4-pentadecylbenzyl phosphate (52):1H-tetrazole (0.149g, 2.134mmol) 
and bis(2-cyanoethyl) N,N-diisopropylphosphoramidite (0.289g, 1.067mmol) were added 
to a solution of compound 27 (0.170g, 0.534mmol) in CH2Cl2 and the mixture was stirred 
for 1 h followed by addition of hydrogen peroxide (0.12ml) to give compound 52. MS 
(ESI) m/z 505.1 ([M + H]). 
 
O,O-bis(2-cyanoethyl)-O-4-pentadecylbenzyl phosphorothioate (54): compound 27 
(0.173g, 0.543mmol) was treated with a mixture of 1H-tetrazole (0.0760g, 2.172mmol) 
and bis(2-cyanoethyl) N,N-diisopropylphosphoramidite (0.371g, 1.086mmol) in 
anhydrous CH2Cl2 and stirred for 1 h followed by addition of sulfur (0.034g, 1.086mmol) 
to give compound 54. MS (ESI) m/z 543.2([M + H]). 
 
Synthesis of 45 and 47:Compound 52 or 54 (1equiv) was dissolved in methanol and 1N 
methanolic KOH (1equiv) was added to the reaction mixture. The completion of the 
reaction was monitored by TLC. The methanol was evaporated and 1N HCl was added 
and the compound was extracted with CHCl3. Purification of the crude residue by 
coloumn chromatography (30:1 CHCl3:MeOH) gave desired compounds 53 and 55 
respectively. 
 
4-pentadecylbenzyl dihydrogen phosphate (53): Compound 53 was obtained as a solid 
(0.087gm, 77%). 1HNMR (500 MHz, CD3OD) δ = 7.337-7.123 (m,overlapping protons, 
4H); 5.075 (overlapping with CD3OD peak , 2H,); 2.598 (t, 2H); 1.593 (m, 2H) 
1.184(s, 24H); 0.890 (t, 3H)MS (ESI) m/z 397.0 [M-H]-. HRMS calcd for C22H38O4P 
([M-H]) 397.2508; Found: 397.2511. 
 
O-4-pentadecylbenzyl O,O-dihydrogen phosphorothioate (55): Compound 55 was 
obtained as a solid (0.073gm, 83%). 1HNMR (500 MHz, CD3OD) δ = 7.321-7.129 
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(m,overlapping protons, 4H); 4.955(d, 2H, J = 4 Hz); 3.581 (t, 2H); 2.586 (t, 2H); 1.580 
(m, 2H); 1.199(s, 24H); 0.889 (t, 3H)MS (ESI) m/z 413.0 [M-H]-. HRMS calcd for 
C22H38O3PS ([M-H]) 413.2279; Found: 413.2281. 
 
 
Biology 
 
Lysophosphatidic acid (18:1), LPC 18:1, and S1P were purchased from Avanti Polar 
Lipids (Alabaster, AL). For calcium mobilization assays, LPA, S1P, and the test 
compounds were prepared as 1 mM stock solutions in phosphate-buffered saline (PBS) in 
an equimolar complex with charcoal-stripped, fatty acid free bovine serum albumin 
(BSA; Sigma, St. Louis, MO). The fluorescent ATX substrate FS-3 was purchased from 
Echelon Biosciences (Salt Lake City, UT). 
 
 
Autotaxin Inhibition Screening Assay 
 
As the first level of screen, 50 µl of recombinant-ATX (2 nM in final concentration) in 
assay buffer [(Tris 50 mM, NaCl 140 mM, KCl 5 mM, CaCl2 1 mM, MgCl2 1 mM (pH 
8.0)] was mixed with 25 µL of FS-3 (Echelon Biosciences Biosciences, Inc., Salt lake 
city, UT; final concentration 1 µM) and 25 µl of test compound dissolved in assay buffer 
with 40 µM bovine serum albumin (Sigma, St. Louis, MO) in 96-well Costar black-well 
plate. FS-3 fluorescence at excitation and emission wavelengths of 485 and 538 nm, 
respectively, were monitored using a FLEXstation II (Molecular Devices, Sunnyvale, 
CA) for 2 h of incubation at 37°C. The differences between time 0 and 120 min were 
calculated individually and normalized to the vehicle control. The mean ± SD of triplicate 
samples was expressed as percentage of ATX activity. The ATX activity in the presence 
of the test compounds was compared to vehicle using the Student’s and p < 0.05 was 
considered significant. 
 
 
Determination of the Mechanism of Autotaxin Inhibition 
 
The mechanism of inhibition of ATX was determined using recombinant, purified human 
ATX and FS-3 as recently described.172,173,175 Final ATX and FS-3 concentrations were 
8.3 nM and 1 µM, respectively and the assay buffer with 15 μM fatty acid free BSA. To 
calculate IC50 full dose responses were determined for the test compounds. In addition, 
the mechanism of inhibition of ATX-mediate hydrolysis of FS-3 was determined by 
varying the concentration (0.3 μM to 20 μM) of substrate in the presence of three 
concentrations of each inhibitor (0, 0.5x and 2x (IC50)). Kinetic data including Vmax and 
Km were determined using KaleidaGraph 4.0 (version 4.03, Synergy Software, Reading, 
PA) after the plots of initial velocities versus substrate concentration in the absence or 
presence of inhibitors were fit to the following equation y = m1*m2*x/(1+m2*x), where 
Km = 1/m2 and Vmax = m1. The average Km for ATX-mediated FS-3 hydrolysis was 
determined to be 2.3 µM and was used in the following calculations. Simultaneous non-
linear regression using WinNonLin® 6.1 (Pharsight, Mountain View, CA) was used to 
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assign the mechanism of inhibition.172,173,175 Ki and Ki' values (the affinity for free 
enzyme and enzyme substrate complex, respectively) were determined by calculating the 
lowest averaged percent residuals for each mechanism derived from curve fitting using 
the Michaelis-Menten equations for competitive, uncompetitive, mixed-mode, and non-
competitive inhibition.  
 
 
Calcium Mobilization Assays 
 
Assays for mobilization of intracellular Ca2 + were performed as described.179,189 Test 
compounds up to a final concentration of 10 µM either alone or mixed with 
respective ~ EC50 concentrations of LPA 18:1 for each of LPA receptor subtype were 
added to cells stably expressing LPA1.2.3.4.5, GPR87, and P2Y10 LPA receptor subtypes.52 
The cells were loaded with Fura-2/AM in Krebs buffer containing 0.001% pluronic acid 
for 1 h, and rinsed with Krebs buffer before measuring Ca2 + mobilization. The Ca2 + 
responses were measured using a Flex Station II fluorescent plate reader (Molecular 
Devices, Sunnyvale, CA). The ratio of peak emissions at 510 nm after 2 min of ligand 
addition was determined for excitation wavelengths of 340 nm/380 nm. All samples were 
run in triplicate, and assays were performed at least two times for each receptor. 
 
 
NPP-6 and NPP-7 Inhibition Assay 
 
Inhibition of NPP6 and NPP7 was evaluated using recombinant, purified proteins, the 
synthetic substrate para-nitrophenylphosphocholine (pNPPC) and a Synergy II plate 
reader (BioTek, Winooski, VT) as we have previously described.172,175 The final 
concentration of each enzyme was 8.3 nM and pNPPC was 10 µM. All analogs were 
tested at single 10 µM concentrations. Absorbance of liberated para-nitrophenol at 405 
nm was determined up to 1 hour (where responses were linear) and was normalized to 
vehicle control. 
 
 
MM1 Hepatoma Cell Invasion of Endothelial Monolayers 
 
The highly invasive MM1 cells originally isolated from the AH130 rat hepatoma cells 
were a kind gift from (Dr. Michiko Mukai, Osaka University171,183). These cells were 
grown in suspension in DMEM supplemented with 10% fetal bovine serum, 2mM 
glutamine, 100 units/ml penicillin and 10µg/ml streptomycin. The isolation and culture of 
mesothelial cells from C57BL/6 mice has been previously described elsewhere HUVECs 
obtained from VEC Technologies Inc., (Rensselaer, NY, USA) were grown in MCDB-
131 complete medium containing 10% fetal bovine serum, 90µg/ml heparin, 10ng/ml 
EGF, 1µg/ml hydrocortisone, 0.2mg/ml EndoGrowth supplement, 100 units/ml penicillin 
G, 100 µg/ml streptomycin and 25µg/ml amphotericin B (all from VEC Technologies). 
Tumor cell invasion was performed by seeding 1.3 x 105 HUVECs (passage 7) into each 
well of a 12-well plate pre-coated with 0.2% gelatin (Sigma) and cultured for 2 days to 
form a confluent monolayer. Mesothelial cells harvested from two-three mice were 
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initially plated in 6-well plates and grown to confluency in DMEM medium 
supplemented with 10% fetal bovine serum in the presence of 100 units/ml penicillin G 
and 10 µg/ml streptomycin. When confluent, the mesothelial cells were split into three 
equal aliquots ( ~ 5x104 cells each) and plated to three wells of a 12-well plate and grown 
to confluence. For all invasion assays, MM1 cells were pre-stained with 2 µg/ml calcein 
AM (Invitrogen, USA) for 2 h, rinsed once, and seeded at a density of 5x104 cells/well 
over the monolayers. Tumor cells were left to invade the HUVEC monolayer for 24 h in 
MCDB-131 complete media containing 1% serum with or without addition of 1.5 µM 
LPC. MM1 cells were plated on the mesothelial monolayers in 2% fetal bovine serum-
supplemented DMEM medium in the presence of 100 units/ml penicillin G and 10 µg/ml 
streptomycin with or without 1.5 µM LPC (5 µM for the mesothelium cells) and invasion 
was allowed to proceed for 20 h. The day after MM1 cell seeding, non-invaded tumor 
cells were removed by repeated five rinses of the HUVEC monolayer (three rinses for the 
mesothelial monolayers) with PBS (containing Ca2 + and Mg2 + ) followed by fixation 
with 10% buffered formalin. The number of tumor cells that penetrated the monolayer 
was photographed under a NIKON TiU inverted microscope using phase-contrast and 
fluorescence illumination in a minimum of five non-overlapping fields at 100x 
magnification. The fluorescent images were overlayed on top of the phase contrast 
images using the Elements BR software (version 3.1x) and the invaded MM1 cells 
showing the characteristic flattened morphology in the plane of focus underneath the 
monolayer were counted. For the invasion assay, LPC dissolved in chloroform was dried, 
re-dissolved in 1mM charcoal-stripped BSA in PBS and added immediately to the 
HUVEC or mesothelium monolayer and co-cultured with MM1 cells with or without the 
ATX inhibitors. The final BSA concentration was 30µM.  
 
 
B16-F10 Murine Melanoma Metastasis Model 
 
All animal procedures were approved by the Institutional Animal Care and Use 
Committee at the University of Tennessee and the M.D. Anderson Cancer Center and 
were consistent with the Guide for the Care and Use of Laboratory Animals (National 
Institutes of Health publication 85-23, revised 1985). Eight-week-old female C57Bl/6 
mice were injected with 5 x 104 cells/animal via tail veins and divided randomly into 4 
groups. Each group then received selective ATX inhibitor (30 or 38b) or dual ATX and 
LPA receptor antagonist LPA-BP170 all at 0.5 mg/kg/injection or vehicle (PBS with 1% 
DMSO) via intraperitoneal injection 30 min after the B16-F10 injection and daily for an 
additional 10 days. Subsequently, animals in all groups were monitored for another 10 
days without treatment. At day 21, all mice were sacrificed and lungs were harvested, 
inflated, and fixed with 10% formalin. The number of metastatic nodules on the lung 
surface was counted. The number of lung nodules was compared to vehicle treated group 
by one-way ANOVA followed by Newman-Keuls multiple comparison test and p < 0.05 
was considered significant. 
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Chapter 4. Discovery of Non-Lipid LPA Analogues 
 
 
The lysophosphatidic acid receptor 2 (LPA2, also known as endothelial differentiation 
gene 4, EDG4) is a G-protein coupled receptor (GPCR) activated by lysophosphatidic 
cid. LPA2 has been shown to be overexpressed in cells from many tumor types including 
breast,190 endometrial,191 ovarian,192 and gastric,193,194 to name a few. LPA2 has also been 
shown to play a role in the development of airway inflammation and pathogenesis of 
asthma.195 Agonists at the LPA2 receptors have a proven therapeutic application of being 
used as a radioprotective agent, whereas antagonists of LPA2 receptors could be potential 
anticancer agents. 
 
A synthesized analog of lysophosphatidic acid (LPA), octadecenyl thiophosphate (OTP) 
(Figure 4.1), showed strong radioprotective action by rescuing cells from apoptosis in 
mice irradiated with lethal doses of γ-irradiation.196 Experiments conducted with 
knockout mice indicate that the molecular target of OTP is the LPA2 receptor. 
Unintended exposure to radiation by means of a nuclear accident, or explosion of a 
nuclear weapon can have devastating consequences on mankind. Octadecenyl 
thiophosphate (OTP) significantly reduces mortality following a lethal dose of LD80/30 
radiation exposure in a mouse model of whole-body irradiation. OTP being a structurally 
similar analog of LPA, we intended to discover a more druglike, non-lipid compounds 
that would be equally efficacious in its pharmacological effects as well as have a benefit 
of being more druglike over OTP. We intended to study the structure activity 
relationships (SAR) and develop new agonists and antagonists of LPA. 
 
Drug discovery is a multi-step process, with final products often taking more than 10 
years to perfect. Finding better and faster methods for identifying promising drug 
candidates is the goal of many in academia and industry.Computational models of LPA 
GPCR were developed by Dr.Parrill and her group and that facilitated to identify receptor 
subtype selective non-lipid antagonists using in silico chemical searches of the NCI 
Developmental Therapeutics Database. Based on the hits that were obtained as a result of 
this virtual screening study, compounds from NCI were obtained and screened for their 
activity as antagonists One of them, NSC # 16540, was initially found to have an 
impressive potency of 100nM as LPA2 antagonist. Hence, we decided to synthesize 
optically pure analogs of NSC # 16540 depicted in Schemes 4.1 and 4.2. However, these 
compounds were tested and found to be inactive at the LPA receptor, We verified the 
data by reordering the original compound from NCI which was also found to be inactive. 
We then focused our efforts on obtaining compounds from the GRI compound library. 
 
 
OP
S
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Figure 4.1. Octadecenyl Thiophosphate (OTP). 
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Scheme 4.1. Synthesis of Compounds 58 and 59. 
Reagents and conditions: a;THF, Et3N, reflux, 16hr. 
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Scheme 4.2. Synthesis of Compounds 64, 65, 66 and 67. 
Reagents and conditions: (a) Pyridine, reflux, 16h, 52%; (b)(i) LiOH, THF/MeOH/H2O;  
(ii) H + , 72%. 
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GRI Compound Library 
 
A very beneficial, research resource was made available to us by collaboration with Dr. 
William Seibel from the University of Cincinnati Genome Research Institute: a world-
class compound library and associated high-throughput screening facilities and expertise. 
We had access to a drug-discovery compound library, high-throughput screening 
technology, and expertise to use the library, which was called the UC/GRI Compound 
Library. This library was carefully designed and maintained in order to provide the ability 
to screen biological targets for novel biochemical tools, probes and drug leads. The 
resource is larger and more targeted than most comparable resources, such as the NIH 
compound repository. The bulk of the compounds in the library are known, 
commercially-available molecules that are very well-characterized. Dr.Tigyi and 
Dr.Parrill's groups had identified a compound obtained from Hit2Lead, H2L5155239, to 
be an antagonist at LPA2 (IC50 = 36.0 nM) and a nonlipid target from the literature197 was 
reported to have an IC50 = 0.017μM. These two compound structures were sent to GRI 
for screening. 
 
 
Screening of GRI Library 
 
A similarity search was performed on the two compounds in Table 4.1. After the initial 
search we were provided with 87 structures from the similarity search results from which 
we selected 12 compounds based on their structural similarities to the compounds in 
Table 4.1. Compounds were supplied as 5 µL of 10 mM solutions in DMSO in 96-well 
plates. These 12 compounds were tested on the five LPA receptors (LPA1-5) and also 
against autotaxin in Dr.Tigyis lab. These compounds were also computationally modeled 
by Dr.Fells and it was noted that the presence of an electron withdrawing group on the 
naphthylamide was responsible for antagonist activity, whereas the absence of the 
electron withdrawing group rendered the compounds an agonist effect at the LPA 
receptors.Along with GRI 125093 (Table 4.2) there was another hit which was identified, 
GRI 948729. However, it was later established that GRI 948729 (Figure 4.2) was a false 
positive. The assay was a fluorescence based assay that utilized an indicator dye Fura-
2AM that monitored the calcium increase/decrease in the assay. Compound 948729 is a 
fluorescent compound and the fluorescence of the compound interfered with the indicator 
dye utilized in the assay. This was later confirmed using another calcium indicator, 
FLIPR® calcium 5 assay kit. The fact that compound 948729 was a false positive was 
brought to light later and both compounds GRI125093 and 948729 were utilized as 
structural fingerprints for the next similarity search as shown in Figures 4.3, 4.4, and 4.5. 
Similarity searching looks for compounds that are most similar to the query compounds 
and each compound from the database is ranked depending on its similarities. The 
underlying principal is that structurally similar compounds usually show similar 
physicochemical properties and biological activities.198 Hence it is common to query 
small molecule database with a probe molecule that possess desirable pharmacological 
activity to find out other chemically similar database entries.199 The similarity search of 
the UC compounds database was carried out by Dr.Seibel and search parameters that 
reflected the structural organization of the molecule like the “structural fingerprints”, e.g 
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Table 4.1. Known LPA Antagonists. 
 
Reference Structure LPA2 LPA1 and LPA3 
Bioorganic & Medicinal 
Chemistry Letters 18 
(2008) 1037–1041 
 
N
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HN
N
N
S
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Cl
Cl
 
0.017μM Not active > 50 μM 
H2L 5155239 
N
O
O
O
OH  
Antagonist 
Ki = 17.0 nM 
IC50 = 36.0 nM 
 
LPA1-no effect 
LPA3-antagonist 
22.7% inhibition 
(30µM)  
 
 
 
 
Table 4.2. GRI Compound 125093.  
 
Compound I.D. Structure RH LPA1 LPA2 LPA3 LPA4 LPA5 ATX 
GRI 125093 
NO O
O OH  
NE Agonist 
(61.0%) 
Agonist 
(44.1%) 
Agonist 
(66.4%) 
Agonist 
(16.4%) 
Agonist 
(35.4%) 
29.1 ± 
4.4%inhibition 
(10 µM) 
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Figure 4.2. GRI 948729. 
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Figure 4.3. Structural Fingerprints for the Similarity Search. 
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Figure 4.4. Similarity Search Protocol. 
 
 
 
 
 
 
 
Figure 4.5. GRI Search Protocol. 
ECFC6: extended connectivity fingerprints counts over 6 atoms; FCFP4: functional class 
connectivity fingerprints over 4 atoms; FCFP6: functional class connectivity fingerprints 
over 6 atoms. 
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the existence of a fused tricyclic or bicyclic ring system ring system, presence of an acid 
moiety etc. these descriptors serve as independent variables in the modern quantitative 
structure activity relationships and the structural fingerprints used in the search method 
are showed in Figure 4.3. Tanimoto coefficients were also used in the similarity search 
and it provides a measure of similarity. 
 
 
Follow-Up Activities 
 
Similarity search was carried out on these compounds GRI 125093 and GRI 948729. 117 
compounds were similar to these two hits and we selected 15 compounds from this list 
based on their structural similarities, and were screened at 1 μM concentration.  
The Similarity Searches were conducted via the protocol , which is expanded to provide 
details of the search in Figure 4.5. With these pharmacological results we planned to 
synthesize compounds 73, 76 and 78. The synthesis of these compounds is shown in 
Schemes 4.3, 4.4, and 4.5. 
 
However, these compounds, 73, 76 and 78 were not found to show any activity at the 
LPA receptors. Further screening of the GRI library lead to the discovery of compound 
GRI977143 depicted in Table 4.3. to be one of the better agonist at LPA receptor. 
We decided to make bioisoteric replacements at the carboxylate functional group of GRI 
977143 and replace it with a phosphoric acid and thiophosphoric acid. The synthesis is 
depicted in Scheme 4.6. 
 
Compound 82 was synthesized by the procedure depicted in literature200 and compounds 
82, 83, 84, 85 and 86 were synthesized using the similar chemistries as before. In the 
biological assays these compounds failed to show any substantial activity. 
 
Experimental Section 
 
 
Biology 
 
The Pharmacological assays were carried out in Dr.Tigyis Laboratory.The test 
compounds were obtained from UC Drug Discovery. The compounds supplied in 10mM 
concentrations. LPA receptor promoted intracellular Ca2 + mobilization was measured for 
LPA receptors in stably expressed cells as previously described. Briefly, cells were plated 
in 96-well plate and cultured overnight. The following day the Ca2 + assay was run using 
sing FLEXstation II (Molecular Devices, Sunnyvale, CA). The cells were loaded with 
fura-2. Changes in the intracellular Ca2 + concentration were then measured by 
determining the ratio of emitted light intensities at 520 nm in response to excitation at 
340 and 380 nm. The compounds were tested for agonist and antagonist activity. Each 
assay was run in quadruplicate. IC50 values were determined concentration curves for 
each compound.  
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Scheme 4.3. Synthesis of Compound 73. 
Reagents and conditions: a) Pyridine, reflux, 5h; b) PBr3,Ether 1 h c) Trimethylphosphite, 
reflux, 18 h; d) i) TMSBr, CH3CN,reflux, 1h; ii) MeOH, 30 min. 
 
 
 
 
70
NO O
OH
NO O
O P O
OH
OH
N P
O
O
CN
CN
+
NO O
O P O
O
O
CN
CN
74 75
76
a
b
 
 
 
Scheme 4.4. Synthesis of Compound 76. 
Reagents and conditions: (a)(i) bis(2-cyanoethyl)-N,N-diisopropylphosphoramidite,1H-
tetrazole, CH2Cl2, rt; (ii) 50% H2O2; (b) (i) KOH, MeOH; (ii) dil HCl. 
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Scheme 4.5. Synthesis of Compound 78. 
Reagents and conditions: (a (i) bis(2-cyanoethyl)-N,N-diisopropylphosphoramidite, 
1H-tetrazole, CH2Cl2, rt; (ii) sulfur, reflux, 2h; (b) (i) KOH, MeOH; (ii) dil HCl. 
 
 
 
 
Table 4.3. GRI 977143 Identified as a Lead Compound for LPA2 Agonist Activity. 
 
Identification Structure 
LPA2 Activity 
EC50 
(µM) 
Emax 
(%) 
OTP OP
S
HO
OH  
0.09 100 
GRI977143 
(Compound 2) 
 
3.3 75 
 
 
  
 56 
H2N
S
OH
SH
OH
OO O
++
NO O
S
O P
S
O
O
NO O
S
O P
S
OH
OH
NO O
S
O P
O
OH
OH
H2N Cl
NO O
S
OH
79
80
81
68
82
83 84
85 86
a
b c d
e d
H2
C CN
H2
C CN
NO O
S
O P
O
O
O H2
C CN
H2
C CN
 
 
 
Scheme 4.6. Synthesis of Compound 84 and 86. 
Reagents and conditions: a) NaOH, MeOH; b)Pyridine, Reflux c) (i) bis(2-cyanoethyl)-
N,N-diisopropylphosphoramidite,1H-tetrazole, CH2Cl2, rt; (ii) sulfur, reflux, 2h; 
(d) (i) KOH, MeOH; (ii) dil HCl; e) )(i) bis(2-cyanoethyl)-
N,N-diisopropylphosphoramidite,1H-tetrazole, CH2Cl2, rt; (ii) 50% H2O2. 
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Chemistry 
 
All starting materials, reagents and solvents were obtained from commercial suppliers 
and were used without further purification. Reactions were performed under an inert 
atmosphere of argon, unless otherwise specified. Routine thin-layer chromatography 
(TLC) was performed on silica gel plates (Analtech, Inc., 250 microns). Flash 
chromatography was conducted on silica gel (Merck, grade 60, 230-400 mesh). 1H NMR 
spectra were recorded on a Bruker ARX 300 spectrometer (300 MHz) or Varian 
spectrometer (400MHz) using DMSO-d6 and CDCl3 as solvents, and spectral data were 
consistent with assigned structures. Chemical shift values were reported as parts per 
million (δ), coupling constants (J) are given in Hz, and splitting patterns are designated as 
follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet. Mass spectra were 
collected on a Brucker ESQUIRE electrospray/ion (ESI) trap instrument in the positive 
and negative modes. 
 
Procedure for the synthesis of compounds 58, 59,60,61: Equimolar quantities of 
compound 56 and 57 were dissolved in anhydrous THF and 0.3 equivalents of 
triethylamine was added to the reaction mixture. The reaction was refluxed for 16 h to 
give compounds 58 and 59 respectively. Two side products, 60 and 61 were also 
charachterized from this reaction. 
 
Compound 58: 1H NMR (300 MHz CD3OD) ; δ = 7.890 (4H, m); 4.958 (1H, m); 3.727 
(3H, s); 2.507-2.572 (2H, m); 2.446-2.333 (2H,m); ESI MS M-H 289.8. 
 
Compound 59: 1H NMR (300 MHz CD3OD) ; δ = 7.890 (4H, m); 4.958 (1H, m); 3.727 
(3H, s); 2.507-2.572 (2H, m); 2.446-2.333 (2H,m) ; ESI MS M-H 289.8. 
 
Compound 60: 1H NMR (300 MHz CD3OD) ; δ = 7-685-7.398 (4H, m); 4.7-4.5(1H, m); 
4.160 (2H,m); 3.737 (3H, s); 2.511 (2H, m); 2.3-2.0 (2H,m); 1.3 (3H,t); ESI MS M + H 
381.1 M + Na 403.1. 
 
Compound 61: 1H NMR (300 MHz CD3OD) ; δ = 7-685-7.398 (4H, m); 4.7-4.5(1H, m); 
4.160 (2H,m); 3.737 (3H, s); 2.511 (2H, m); 2.3-2.0 (2H,m); 1.3 (3H,t); ESI MS M + H 
381.1 M + Na 403.1. 
 
Synthesis of 64 and 65: Equimolar amounts of L-Glutamic acid and phthalic anhydride 
were heated under reflux in anhydrous pyridine for 24 hrs (under argon atmosphere). The 
pyridine was evaporated and the reaction mixture was extracted with chloroform and 
washed first with 1N HCl and then with 1N NaOH solution. The organic layer was dried 
over anhydrous sodium sulfate and the solvent was removed under pressure. The residue 
was purified by column chromatography on silica gel (eluted with Hexanes/Ethylacetate 
(1.5:1) to give Phthaloylglutamic dimethyl ester. 
 
Compound 64 :Phthaloylglutamic dimethyl ester.(52.98% yield) 1H NMR (300 MHz 
CDCl3) ; δ 2.38-2.41 (2H, m), 2.45-2.67 (2H, m), 3.623 (3H, s), 3.74 (3H, s), 4.92-4.95 
(1H, q), 7.74-7.78 (2H, m), 7.86-7.89 (2H, m). 
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Compound 65: Phthaloylglutamic dimethyl ester.(44.025% yield) 1H NMR (300 MHz 
CDCl3) ; δ 2.40-2.51 (2H, m), 2.53-2.69(2H, m), 3.628 (3H, s), 3.754 (3H, s), 4.91-4.96 
(1H, q), 7.73-7.78 (2H, m), 7.793-7.796(2H, m). 
 
Synthesis of D and L Phthaloyl Glutamic acid (66,67): To L(or D)-Phthaloylglutamic di-
methyl ester, add THF at 0°C and then add 1N LiOH dropwise, under argon atmosphere. 
Stir for 30 min. Solvent was evaporated and extracted with ethylacetate. The Ethylacetate 
layer was washed with 1N HCl (PH 1-2). The Ethyl acetate was then evaporated in vacuo 
to give product. 
 
Compound 66: (54.72% yield) 1H NMR (300 MHz CDCl3) ; δ 2.07-2.10 (2H, m), 
2.38-2.51(2H, m), 4.34-4.41(1H, q), 7.43-7.62 (2H, m), 7.77-8.55(2H, m); 12.55 (2H, s) 
Compound 67: (72.42% yield) 1H NMR (300 MHz CDCl3) ; δ 2.07-2.10 (2H, m), 
2.38-2.51(2H, m), 4.34-4.41(1H, q), 7.43-7.62 (2H, m), 7.77-8.55(2H, m); 12.55 (2H, s). 
 
Procedure for the synthesis of 70 and 82: Equimolar quantities of the anhydride and the 
primary amine were refluxed in pyridine for four hours to give pure products. No further 
purification was needed. 
 
Compound 70: 1H NMR (300 MHz CDCl3) ; δ = 8.634-8.613 (2H, d, J = 6.3Hz); 8.258-
8.233 (2H, d, J = 7.5Hz); 7.779 (2H, t); 4.362 (2H, t); 3.59 (2H, t); 3.2-3.1 (1H, s); 2.002 
(2H, p). 
 
Synthesis of 72: Compound 70 was first converted to its bromide derivative by the 
addition of 0.3 Equivalents of PBr3, and using diethethyl ether as solvent, the reaction was 
quenched by the addition of water at 0°C. the compound was extracted and dried over 
magnesium sulfate. The dry bromide derivative was then taken into a flask and 
trimethylphosphite was added to it (large excess) and refluxed for 18h to obtain 
compound 72: 1H NMR (300 MHz CDCl3) ; δ = 8.634-8.613 (2H, d, J = 6.3Hz); 
8.258-8.233 (2H, d, J = 7.5Hz); 7.779 (2H, t); 4.348 (2H, t); 4.243 (2H, t); 3.79 (6H, d, J 
= 12); 2.177 (2H, p). 
 
Synthesis of 73: To a suspension of phosphonate derivative 72 (1 equiv) in anhydrous 
acetonitrile, TMSBr (2.5 equiv) was added and the reaction mixture was refluxed for 1 h. 
The acetonitrile was then evaporated under reduced pressure and MeOH was added to the 
residue and stirred for 30 minutes at room temperature. The desired product was obtained 
in good yield after filtration of MeOH solution as a white solid. 1H NMR (300 MHz 
dmso) ; δ = 8.634-8.613 (2H, d, J = 6.3Hz); 8.258-8.233 (2H, d, J = 7.5Hz); 7.779 (2H, t); 
4.348 (2H, t); 4.243 (2H, t); 3.325 (2H, s);  2.177 (2H, p). 
 
General procedure for 76 and 86: 1H-tetrazole ( 2.134mmol) and bis(2-cyanoethyl) 
N,N-diisopropylphosphoramidite (1.067mmol) were added to a solution of compound 70 
or 82 ( 0.534mmol) in CH2Cl2 and the mixture was stirred for 1 h followed by addition of 
hydrogen peroxide (0.12ml) to give compound77 and 85 respectively. Compound 75 or 
85 (1equiv) was dissolved in methanol and 1N methanolic KOH (1equiv) was added to 
the reaction mixture. The completion of the reaction was monitored by TLC. The 
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methanol was evaporated and 1N HCl was added and the compound was extracted with 
CHCl3. Purification of the crude residue by coloumn chromatography (30:1 
CHCl3:MeOH) gave desired compounds 76 and 86 respectively. 
 
Compound 76: 1H NMR (300 MHz CD3OD) ; δ = 8.431-8.407 (2H, d, J = 7.2Hz); 
8.241-8.214 (2H, d, J = 8.1Hz); 7.881 (1H,s); 7.708 (2H, t); 4.221 (2H, t); 4.070 (2H, t); 
2.033 (2H, p). 
 
Procedure for 78 and 84: 1H-tetrazole ( 2.134mmol) and bis(2-cyanoethyl) N,N-
diisopropylphosphoramidite (1.067mmol) were added to a solution of compound 70 or 82 
(0.534mmol) in CH2Cl2 and the mixture was stirred for 1 h followed by addition of sulfur 
(4Eq)and the reaction mixture was refluxed for 2 hr to give compound 77 and 83 
respectively. Compound 77 or 83 (1equiv) was dissolved in methanol and 1N methanolic 
KOH (1equiv) was added to the reaction mixture. The completion of the reaction was 
monitored by TLC. The methanol was evaporated and 1N HCl was added and the 
compound was extracted with CHCl3. Purification of the crude residue by coloumn 
chromatography (30:1 CHCl3:MeOH) gave desired compounds 76 and 86 respectively. 
 
Compound 77: 1H NMR (300 MHz CDCl3) ; δ = 8.634-8.613 (2H, d, J = 6.3Hz); 
8.258-8.233 (2H, d, J = 7.5Hz); 7.779 (2H, t); 4.348 (8H, overlapping protons); 4.243 
(2H, t); 2.805 (4H, t); 2.173 (2H, p). 
 
Compound 78:1H NMR (300 MHz CD3OD) ; δ = 8.431-8.407 (2H, d, J = 7.2Hz); 
8.241-8.214 (2H, d, J = 8.1Hz); 7.881 (1H,s); 7.708 (2H, t); 4.221 (2H, t); 4.070 (2H, t); 
2.033 (2H, p). 
 
Compound 82:1H NMR (400 MHz CDCl3) ; δ = 8.573-8.556 (2H, d); 8.206-8.185 (2H, 
d); 7.732 (2H, t); 7.433 (2H,d); 7.203 (2H,m) 4.833 (2H, s); 4.297 (2H, t); 3.040 (2H, t);  
2.047 (2H, p). 
 
Compound 84:1H NMR (400 MHz CD3OD) ; δ = 8.432 (4H, m); 7.732 (2H, t); 
7.470-7.219 (4H,m); 4.921-4.905 (2H, d); 4.185 (2H, t); 3.040 (2H, t); 1.945 (2H, p). 
 
Compound 86: 1H NMR (400 MHz CD3OD) ; δ = 8.546-8.390 (4H, m); 7.732 (2H, t); 
7.470-7.219 (4H,m); 4.921-4.905 (2H, d); 4.185 (2H, t); 3.040 (2H, t); 1.945 (2H, p). 
 
 
Conclusion 
 
Drug discovery is a multi-step process, with final products often taking more than a 
decade to perfect. Finding better and faster methods for identifying promising drug 
candidates is the goal of many in academia and industry. A rapid screening method, such 
as the library provided by the GRI, a high-throughput screening system, adds to the drug-
discovery arsenal. Once identified, potentially useful compounds, or “drug candidates,” 
are then further tested in specific disease models, licensed or sold to biotech or 
pharmaceutical companies for continued development. This research endeavour has 
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enabled us to identify lead molecules of the LPA receptors. The screening of these 
compounds also unfolded some interesting structure activity relationships. Although I 
was not able to make potent compounds at the LPA receptors, I believe further 
optimization of the medicinal chemistry targets will yield better, non lipid analogs of 
LPA. 
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The first two projects discussed in this dissertation deal with the development of 
autotaxin inhibitors. These projects play a vital role in the need for continuing research to 
better understand the pharmacology of cancer and aim at designing newer antineoplastic 
drugs that would improve the survival and outcomes in cancer patients. The first two 
projects I have worked on both involved synthesis of autotaxin inhibitors but both 
focused on different core structures. The first project I worked on focused on the 
synthesis of stereoisomers of 3-CCPA, which was previously shown to have potent 
autotaxin inhibitory effect. My second project involved the design of novel benzyl and 
naphthalene-methyl phosphonic acid inhibitors as autotaxin inhibitors and we were 
successful in identifying a very potent and promising ATX inhibitor. The third project 
involved identifying LPA2 analogs by screening the GRI compound library and 
undertaking the development of non-lipid LPA analogs. The purpose of this chapter is to 
offer a look into the crucial aspects of each project and to discuss potential future actions 
that can keep these projects successful. 
 
 
3-CCPA Project 
 
This project was discussed in Chapter 2 of this dissertation. It dealt with the synthesis of 
stereoisomers of 3-CCPA to further understand the therapeutic utility of racemic 3-
CCPA. 3-carba analogs of CPA lack significant agonist activity at LPA receptors yet are 
potent inhibitors of ATX activity, LPA production, and A2058 melanoma cell invasion in 
vitro and B16F10 melanoma cell metastasis in vivo. We found that both the R and the S 
stereoisomer inhibited ATX in vitro as well as the B16F10 melanoma metastasis in vivo 
with equal efficacy. The two isomers failed to show any significant stereospecificity. 
However, at the LPA5 GPCR, the S-stereoisomer (S-3-CCPA) showed significantly 
higher efficacy. This was the first study indicating the stereospecific agonist action on 
LPA5 receptors. 
 
 
Benzyl and Naphthalene-Methyl Phosphonic Acid Inhibitors of Autotaxin Project 
 
This project was discussed in Chapter 3 of this dissertation. The ATX-LPA-LPA receptor 
axis is a potential therapeutic target for the management of cancer metastases and 
therapeutic resistance. Ferry and colleagues described a ATX inhibitor 
4-tetradecanoylaminobenzyl phosphonic acid (S32826) that possessed nanomolar activity 
in vitro.177 Unfortunately, S32826 failed to show activity in cellular and in vivo systems.  
We hypothesized that hydrolysis of the amide bond present in S32826 could be the 
reason for its instability and thus lack of activity in cellular systems. To overcome the 
presumed lack of stability of S32826, we designed analogs that were expected to be more 
stable than the parent compound and we were successful in generating a panel of analogs 
that inhibit ATX with potencies comparable to that of S32826. These stabilized analogs 
inhibit ATX via a mixed-mode mechanism in vitro without any effect on the related 
Chapter 5. Discussion of Dissertation 
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lysophospholipid phosphodiesterases, NPP6 and NPP7 or on LPA receptors (LPAR). 
Two of these compounds, 30 and 38b inhibited ATX-dependent invasion of rat MM1 
hepatoma cells of mesothelial cell and human umbilical cord vascular endothelialcell 
(HUVEC) monolayers in vitro. In addition, 30and 38b showed a profound reduction in 
lung foci in vivo using the B16-F10 syngeneic melanoma metastasis model in C57BL/6 
mice. Based on these results compounds 30 and 38b represent promising leads for further 
synthetic improvement and also provide proof of principle that ATX inhibitors offer 
therapeutic utility in the control of cancer metastasis in vivo. Subsequently, we generated 
analogs of compounds 22 and 38b and examined their inhibition of ATX. The 
modifications were either in the aliphatic chain, the linker of the phosphate moiety, or on 
the phosphate moiety itself. 
 
The most effective analogs based on the single 10-µM dose inhibition assay were 
extensively characterized to determine IC50, Ki, and Ki’ values against ATX-mediated 
hydrolysis of FS-3. Replacement of the amide with a sulfonamide (12) reduced potency. 
Introduction of an ether (18) or alkene (26) connecting the hydrocarbon chain to the 
benzyl ring decreased the potency compared to the simple aliphatic chain.  Linkage of the 
phosphate moiety in compound 53 through a methyl phosphonate reduced efficacy. 
However, converting the phosphate to a thiophosphate (55) in this scaffold increased 
efficacy at 10 µM 5.6-fold. α-Halogenation of the linker methyl group generally 
decreased potency of compounds 49, 50, and 51 relative to compound 30. Insertion of a 
α-hydroxyl group into the linker methylene increased the potency of this analog but it did 
not surpass that of compound 30. 
 
Modification of the side chain at position 6 of the naphthalene-2yl-methyl phosphonic 
acid scaffold showed that the 10-carbon side chain was more effective than the 11 carbon 
chain and that incorporation of an alkene had differential effects depending on the chain 
length (decreased efficacy of compound 38a relative to 42a, but increased efficacy of 38b 
over 42b). Analysis of the seven analogs showed that compound 30 in the benzyl 
phosphonic acid series and compound 38b in the naphthalene-methyl phosphonic acids 
were the most potent analogs with respect to ATX inhibition. Future research should 
involve synthesis of analogs of compound 30 by varying the carbon chain lengths and 
designing more molecules so as to provide better insight in the structure activity 
relationship, unearthing a lead molecule in the quest for the discovery of anti cancer 
drugs. 
 
 
Non–Lipid LPA2 Analogs Project 
This project was discussed in Chapter 4 of this dissertation. This project involved various 
steps like in-silico screening of compounds, selecting and testing the compounds from the 
GRI library based on the structural similarities, obtaing a hit in pharmacological assays 
and developing the hit into a lead. Drug discovery is a multi-step process. Finding better 
and faster methods for identifying promising drug candidates is the goal of many in 
academia and industry. A rapid screening method, such as the library provided by the 
GRI, a high-throughput screening system, adds to the drug-discovery arsenal. Once 
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identified, potentially useful compounds, or “drug candidates,” are then further tested in 
specific disease models, licensed or sold to biotech or pharmaceutical companies for 
continued development This research endeavour has enabled us to identify lead 
molecules of the LPA receptors. The screening of these compounds also unfolded some 
interesting structure activity relationships. Although I was not able to make potent 
compounds at the LPA receptors, I believe further optimization of the medicinal 
chemistry targets will yield better, non lipid analogs of LPA. 
 
 
Final Thoughts  
 
During my tenure at graduate school, I have had the pleasure of being able to conduct 
cutting edge research in an area that shows a clear need for new development. Although 
my training has been as a synthetic medicinal chemist, my educational experience has 
allowed me to become a well-rounded scientist.  
 
Medicinal chemistry is an interdisciplinary science. It utilizes knowledge from a variety 
of scientific fields in order to effectively create a well-rounded scientist. Working as a 
medicinal chemist involves working in an interdisciplinary environment where 
collaboration is the key to success. A medicinal chemist is a person who can bridge some 
of the gaps between chemistry and biology. This ability makes a well-trained medicinal 
chemist an invaluable asset to any interdisciplinary research team. The projects that I 
have worked on during my time in graduate school have been projects that have afforded 
me ample hands-on experience in the chemistry laboratory. I have had the opportunity to 
expand my knowledge base on a variety of different synthetic techniques. In addition to 
my expanded chemistry knowledge, I have been able to grow my knowledge on the 
pharmacological significance for these projects. These projects allowed me to build up a 
significant knowledge base in the understanding of LPA and its pharmacological 
significance. The ability to work on projects that required me to expand my knowledge 
has really benefited me in my quest to become a well-rounded scientist. It is my goal to 
continue to grow my knowledge base for each project that I undertake during my 
professional career.  
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